2-Pyridone derivatives, their preparation method and their application in medicine

2-pyridone derivatives address the limitations of existing thyroid hormone agonists by offering high activity and selectivity, effectively treating metabolic disorders and thyroid-related diseases with reduced side effects.

JP7588239B2Active Publication Date: 2024-11-21KPC PHARM INC +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2023540790
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-12-30
Filing Date
2021-12-28
Publication Date
2024-11-21
Estimated Expiration
2041-12-28

AI Technical Summary

Technical Problem

Existing thyroid hormone agonists suffer from issues of efficacy, safety, and selectivity, failing to effectively target thyroid hormone receptors while avoiding adverse side effects.

Method used

Development of 2-pyridone derivatives with specific structural formulations, represented by Formula I, which act as high-activity and selective agonists for thyroid hormone receptors, potentially treating conditions like obesity, hyperlipidemia, and cardiovascular diseases.

Benefits of technology

The 2-pyridone derivatives exhibit high activity and selectivity for thyroid hormone receptors, providing therapeutic benefits in treating metabolic disorders and thyroid-related diseases with reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588239000001
    Figure 0007588239000001
  • Figure 0007588239000002
    Figure 0007588239000002
  • Figure 0007588239000003
    Figure 0007588239000003
Patent Text Reader

Abstract

The present invention provides a 2-pyridone derivative having a structure represented by Formula I, or a stereoisomer or a pharma- ceutically acceptable salt thereof. Activity experiments show that the 2-pyridone derivatives provided by the present invention have high activity and selectivity, and can be used to treat diseases related to the thyroid hormone receptor.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] cross reference This application claims priority from a Chinese patent application filed with the China Patent Office on December 30, 2020, bearing application number 202011609510.0 and titled "2-Pyridone Derivatives and Their Preparation Methods and Applications in Medicine," the entire contents of which are incorporated herein by reference.

[0002] The present invention relates to the technical field of pharmaceuticals, in particular to compounds that can be used as novel agonists of the THR β receptor, their preparation methods, and uses, and more particularly to 2-pyridone derivatives, their preparation methods, and pharmaceutical applications. [Background technology]

[0003] Thyroid hormones are important for normal growth and development and for maintaining metabolic balance (Physiological Reviews 2001, 81(3), 1097-1126). Thyroid hormones are produced by the thyroid gland and secreted into the circulatory system (hypothalamus / pituitary / thyroid axis) in two different forms, T4 and T3. T4 is the main form secreted by the thyroid gland, while T3 is the more physiologically active form. T4 is converted to T3 by tissue-specific deiodinases, which are present in all tissues but primarily in the liver and kidney.

[0004] [ka]

[0005] Circulating levels of thyroid hormones are tightly regulated by feedback mechanisms in the hypothalamus / pituitary / thyroid axis. Thyroid dysfunction leading to hypothyroidism or hyperthyroidism has profound effects on the heart, weight, metabolism, metabolic rate, body temperature, cholesterol, bones, muscles, and behavior.

[0006] The physiological activity of thyroid hormones is mediated by thyroid hormone receptors (THRs) (Endocrine Reviews (1993) 14 348-399). THRs belong to the receptor family, and their α and β forms are encoded by different genes located on human chromosomes 17 and 3. Different protein subtypes are generated after selective cleavage of the primary transcript, resulting in two subtypes per gene: THRα1, THRα2, THRβ1, and THRβ2. THRβ1 and THRβ2 are derived from differential promoter expression, and these two subtypes differ only in their amino termini. THRα1 and THRα2 are derived from differential splicing of precursor mRNAs and differ primarily in their carboxyl termini. THRα1, THRβ1, and THRβ2 can bind to thyroid hormones. THRβ is distributed mainly in the liver, kidney, pituitary gland, and cerebral tissues and plays an important role in regulating the actions of TRH and thyroxine in the liver, while THRα is widely distributed throughout the body and is associated with extrahepatic cardiovascular and skeletal / muscular side effects (Drugs (2017) 77 1613-1621). Therefore, thyroid hormone analogs that can avoid the adverse effects of hyperthyroidism and hypothyroidism while maintaining the beneficial effects of thyroid hormones could be used to treat metabolic diseases, including obesity, hyperlipidemia, hypercholesterolemia, and diabetes, as well as other diseases such as hepatic steatosis, nonalcoholic steatohepatitis (NASH), atherosclerosis, cardiovascular disease, hypothyroidism, thyroid cancer, and thyroid diseases.

[0007] The therapeutic use of thyroid hormone itself is limited by adverse side effects related to hyperthyroidism, particularly cardiovascular toxicity. In the prior art, a series of thyroid hormone agonists have been developed, mostly based on the structure of the natural ligand T3 of the THR receptor, and for example, thyroid hormone analogs different in structure from the compounds of the present invention have been disclosed (Agricultural and Biol. Chem. 1974, 38(6), 1169; J. Med. Chem. 1989, 32, 320; J. Med. Chem. 2014, 57(10), 3912; WO2007009913; WO2010122980). Among these, Example 8 (compound 31) disclosed in WO2007009913 is MGL-3196, the first orally administered small molecule hepatic thyroid hormone receptor β subtype (THR-β) selective agonist currently in clinical use. Preclinical toxicology and phase I clinical data have shown that MGL-3196 significantly reduces LDL cholesterol, triglycerides, and lipid proteins as a potential treatment for non-alcoholic steatohepatitis (NASH) and dyslipidemia, making it an ideal candidate drug for NASH patients at low cardiovascular risk and for patients receiving moderate statin doses or who are intolerant to statins. Phase II clinical data have shown that adverse events (AEs) were mainly mild (85%) and moderate (15%), with three serious cases unrelated to treatment. Furthermore, in WO2009037172A1 and CN 110938094 A, the structure of MGL3196 is modified by substituting the nitrogen atom of the pyridazine ring to form an inactive or low-activity prodrug of MGL3196, which is metabolized in the body to form a drug substance, thereby achieving technical effects such as improving the absorption, distribution, transport and metabolic processes of the drug in the body, improving bioavailability, improving the selectivity of the drug's action on the target site, reducing the toxic side effects of the drug, prolonging the action time, and reducing the impact on food.

[0008] Subsequently, documents such as WO2020073974, CN 111320609 A, and WO2019240938 have made a series of structural modifications to the pyridazone ring in different directions based on the MGL-3196 structure, but the parent nucleus always has a pyridazone structure similar to the MGL-3196 structure. WO2020169069 discloses pyridine and pyridone-like structures, but the biological activity of THRβ and the selectivity of THRβ / THRα are both reduced, and especially after the nitrogen atom on the pyridone is substituted, the pharmacological activity is almost lost.

[0009] [ka]

[0010] The compounds and experimental drugs disclosed in these prior art still have problems in terms of efficacy, safety, selectivity, etc., and therefore there is a need to continue to discover and develop novel highly active and highly selective compounds that can retain the beneficial effects of thyroid hormone while avoiding the adverse effects, for use in treating diseases related to the thyroid hormone receptor. Summary of the Invention [Problem to be solved by the invention]

[0011] In view of the above circumstances, the technical problem to be solved by the present invention is to provide 2-pyridone derivatives with high activity and selectivity, a method for preparing the same, and their application in medicine. [Means for solving the problem]

[0012] To achieve the above object, the present invention provides a 2-pyridone derivative having a structure represented by formula I, or a stereoisomer or pharmaceutically acceptable salt thereof.

[0013] [ka]

[0014] In the formula, R1 is C 1~6 Alkyl group, C 3~6 saturated or unsaturated cycloalkyl groups, C 5~10 Aryl group or C 5~10 and the heteroaryl group is selected from the group consisting of the above C 1~6 The alkyl group may be one or more of a halogen, a deuterium, a hydroxyl group, an alkoxy group, an oxo group, an amino group, a C 3~6 It may be optionally substituted with a cycloalkyl group, a 5- to 10-membered aryl group, or a 5- to 10-membered heteroaryl group, and 3~6 The saturated or unsaturated cycloalkyl group may be substituted with one or more groups selected from halogen, deuterium, a hydroxyl group, an alkoxy group, an oxo group, and an amino group, and the C 5~10 Aryl group, C 5~10 The heteroaryl group, 5- to 10-membered aryl group or 5- to 10-membered heteroaryl group may be one or more halogen, substituted or unsubstituted C 1~6 Alkyl groups, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 optionally substituted with alkoxy, cyano, hydroxyl, or amino groups; R2 is hydrogen or C 1~6 alkyl groups, R3 is hydrogen, halogen, C 1~6 Alkyl group or C 3~6 cycloalkyl groups, R4 is independently hydrogen, a hydroxyl group, or C 1~6 Alkyl groups, halogens, C 1~6 Alkoxy group, C 3~6 cycloalkyl groups, or two adjacent R4 are C 3~6 Forms a cycloalkyl group, wherein the C 1~6 Alkyl group, C 3~6 Cycloalkyl group or C 1~6 The alkoxy group may be further optionally substituted with one or more hydroxyl groups, halogens, n is 1, 2 or 3; R5 is hydrogen, cyano group, carboxyl group, C1~6 Alkyl group, C 3~6 cycloalkyl groups, 1~6 Alkyl group, C 3~6 The cycloalkyl group may be one or more of a halogen, a hydroxyl group, a C l~6 optionally substituted with alkoxy groups; R6 is hydrogen, C 1~6 alkyl groups, L is selected from -CH2-, -O-, -CF2- or -S-; X is selected from O or S; Alternatively, R1 and R2 together with the atom to which they are attached form a 4-10 membered heterocycloalkyl group, which may further contain 0, 1 or 2 optional oxygen, sulfur and nitrogen atoms in addition to the nitrogen atom originally attached to R1, and which may further contain one or more C l optionally substituted with a -C6 alkyl group, a hydroxyl group, a halogen, a cycloalkyl group; R3 is C 1~6 When R1 is an alkyl group and / or a C3-C6 cycloalkyl group, R1 is C 1~6 Alkyl group, C 3~6 It is not a saturated or unsaturated cycloalkyl group.

[0015] In the present invention, preferably, 5~10 Aryl group, C 5~10 The heteroaryl group, 5- to 10-membered aryl group or 5- to 10-membered heteroaryl group may be one or more halogen, substituted or unsubstituted C 1~6 Alkyl groups, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 optionally substituted with an alkoxy group or a cyano group; The aforementioned C 1~6 Alkyl group, C 3~6 Cycloalkyl groups, C 1~6 The alkoxy group may be optionally substituted with one or more F atoms.

[0016] In the present invention, the substituents of the substituted or unsubstituted C1-C6 alkyl group, substituted or unsubstituted C3-C6 cycloalkyl group, and substituted or unsubstituted C1-C6 alkoxy group are preferably one, two, or three fluorine atoms.

[0017] In the present invention, R1 is preferably selected from a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a neopentyl group, -CH(CH2CH3)2, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopentenyl group, a cyclohexenyl group, a phenyl group, a thienyl group, and a thiazolyl group.

[0018] Preferably, the methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, -CH(CH2CH3)2 is one or more of halogen, deuterium, hydroxyl group, C 1~6 Alkoxy group, oxo group, amino group, C 3~6 It may be optionally substituted with a cycloalkyl group, a phenyl group, a naphthyl group, a pyridine group or a pyrrolyl group.

[0019] Preferably, the phenyl, naphthyl, pyridine or pyrrolyl group further comprises one or more halogen, substituted or unsubstituted C 1~6 Alkyl groups, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 It may be optionally substituted with an alkoxy group, a cyano group, a hydroxyl group, or an amino group.

[0020] The above alkoxy group is C 1~6 An alkoxy group is preferred.

[0021] C according to the present invention 1~6The alkoxy group is preferably a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group or a pentyloxy group.

[0022] C above 3~6 The cycloalkyl group is preferably a cyclopropyl group, a cyclobutyl group, a cyclopentyl group or a cyclohexyl group.

[0023] Preferably, the cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cyclopentenyl group, cyclohexenyl group may contain one or more of halogen, deuterium, hydroxyl group, C 1~6 It may be optionally substituted with an alkoxy group, an oxo group, or an amino group.

[0024] C above 1~6 The alkoxy group is preferably a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group or a pentyloxy group.

[0025] The phenyl, thienyl and thiazolyl groups may each be substituted with one or more halogen atoms, substituted or unsubstituted C 1~6 Alkyl groups, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 It may be optionally substituted with an alkoxy group, a cyano group, a hydroxyl group, or an amino group.

[0026] C above 1~6 The alkyl group is preferably a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group or a tert-butyl group.

[0027] C above 1~6 The alkoxy group is preferably a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group or a pentyloxy group.

[0028] C above 3~6The cycloalkyl group is preferably a cyclopropyl group, a cyclobutyl group, a cyclopentyl group or a cyclohexyl group.

[0029] C above 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 The cycloalkyl group may further be optionally substituted with 1 to 3 fluorine atoms.

[0030] Alternatively, R1 and R2 together with the atom to which they are attached form a 4- to 10-membered heterocycloalkyl group, preferably a 5- or 6-membered monocyclic heterocyclic group, more preferably a tetrahydropyrrolyl group.

[0031] The heterocycloalkyl group may further contain, in addition to the nitrogen atom originally connected to R, 0, 1, or 2 optional oxygen, sulfur, and nitrogen atoms, and the heterocycloalkyl group may further contain one or more C l It may be optionally substituted with a -C6 alkyl group, a hydroxyl group, a halogen, or a cycloalkyl group.

[0032] More preferably, one or more C 1~3 Alkyl group, halogen or C 3~6 It is substituted with a cycloalkyl group.

[0033] More preferably, it is substituted with one or more of fluorine, chlorine, bromine, methyl group, ethyl group, propyl group, isopropyl group, cyclopropyl group, cyclobutyl group, cyclopentyl group, or cyclohexyl group.

[0034] In the present invention, R2 is preferably hydrogen, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a neopentyl group, or —CH(CH2CH3)2, and more preferably hydrogen.

[0035] In the present invention, R3 is preferably selected from hydrogen, fluorine, chlorine, bromine, iodine, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, —CH(CH2CH3)2, cyclopropyl group, cyclobutyl group, cyclopentyl group, and cyclohexyl group, and more preferably hydrogen, fluorine, chlorine, methyl group, or cyclopropyl group.

[0036] In the present invention, R4 is preferably fluorine, chlorine, bromine or iodine.

[0037] More preferably, R4 is ortho-dihalogen at the L position. Specifically, R4 is ortho-difluoro, ortho-dichloro, or ortho-dibromo at the L position.

[0038] More preferably, R4 is chlorine and the substitution position is at the ortho position of the L position, that is, a 2,6-disubstituted compound as shown in the following structure (an example in which L is O).

[0039] [ka]

[0040] In the present invention, the R5 is a cyano group or C 1~6 It is preferably selected from alkyl groups.

[0041] The aforementioned C 1~6 The alkyl group may be optionally substituted with one or more halogen, hydroxyl or amino groups.

[0042] More preferably, R5 is selected from hydrogen, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, or -CH(CH2CH3)2.

[0043] Preferably, the methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group or -CH(CHCH) may optionally be substituted with one to three fluorine atoms.

[0044] In some specific embodiments of the present invention, R5 is a cyano group, a methyl group, a monofluoromethyl group, a difluoromethyl group, or a trifluoromethyl group.

[0045] In the present invention, R6 is preferably hydrogen, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a neopentyl group, or -CH(CH2CH3)2, and more preferably hydrogen.

[0046] The above n is preferably 1, 2 or 3, and more preferably 2.

[0047] The aforementioned L is preferably -CH2-, -O-, -CF2- or -S-, and more preferably -O-.

[0048] The above X is preferably O or S, and more preferably O.

[0049] In the present invention, the 2-pyridone derivative preferably has any one of the structures of formulae IIa to IIc.

[0050] [ka]

[0051] In the formula, R 1a is C 1~6 Alkyl group, C 3~6 saturated or unsaturated cycloalkyl groups, 1~6The alkyl group may further comprise one or more of a halogen, a deuterium, a hydroxyl group, an alkoxy group, an oxo group, an amino group, a C 3~6 It may be optionally substituted with a cycloalkyl group, a 5- to 10-membered aryl group, or a 5- to 10-membered heteroaryl group, and 3~6 The saturated or unsaturated cycloalkyl group may further be optionally substituted with one or more halogen, deuterium, hydroxyl, alkoxy, oxo, or amino groups; The 5- to 10-membered aryl group or the 5- to 10-membered heteroaryl group may be substituted with one or more halogen atoms, substituted or unsubstituted C 1~6 Alkyl groups, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 optionally substituted with alkoxy, cyano, hydroxyl, or amino groups; R 1b is C 5~10 Aryl group or C 5~10 heteroaryl groups, 5~10 Aryl group or C 5~10 The heteroaryl group may further comprise halogen, substituted or unsubstituted C 1~6 Alkyl groups, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 may be optionally substituted with one or more selected from an alkoxy group, a cyano group, a hydroxyl group, and an amino group; In Formula IIc, the A ring is a 4-10 membered heterocycloalkyl group containing a nitrogen-bonded ring, wherein the 4-10 membered heterocycloalkyl group may further contain, in addition to the original nitrogen-bonded ring, 0, 1, or 2 optional oxygen, sulfur, and nitrogen atoms, and the heterocycloalkyl group may further contain one or more C l optionally substituted with a -C6 alkyl group, a hydroxyl group, a halogen, a cycloalkyl group; R5 is hydrogen, cyano group, carboxyl group, C 1~6 Alkyl group, C 3~6 cycloalkyl groups,1~6 Alkyl group, C 3~6 The cycloalkyl group may be one or more of a halogen, a hydroxyl group, a C l~6 It may be optionally substituted with an alkoxy group.

[0052] The above alkoxy group is C 1~6 An alkoxy group is preferred.

[0053] In the present invention, the above-mentioned R 1a is preferably selected from a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a neopentyl group, —CH(CHCH) , a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopentenyl group, and a cyclohexenyl group.

[0054] The methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, -CH(CH2CH3)2 may be one or more of halogen, deuterium, hydroxyl group, C 1~6 Alkoxy group, oxo group, amino group, C 3~6 It may be optionally substituted with a cycloalkyl group, a phenyl group, a naphthyl group, a pyridine group, or a pyrrolyl group.

[0055] In the present invention, the phenyl group, naphthyl group, pyridine group, and pyrrolyl group preferably contain one or more halogen atoms, substituted or unsubstituted C 1~6 Alkyl groups, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 It may be optionally substituted with an alkoxy group, a cyano group, a hydroxyl group, or an amino group.

[0056] In the present invention, preferably, 1~6 Alkyl group, C 3~6 Cycloalkyl groups, C 1~6The alkoxy group may further be optionally substituted with one or more F atoms.

[0057] The cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, and cyclohexenyl groups may each be substituted with one or more of a halogen, a deuterium, a hydroxyl group, a C 1~6 It may be optionally substituted with an alkoxy group, an oxo group, or an amino group.

[0058] The aforementioned R 1b is C 5~10 Aryl group or C 5~10 It is preferably a heteroaryl group.

[0059] In the present invention, preferably, 5~10 Aryl group, C 5~10 Heteroaryl groups may include one or more halogen, substituted or unsubstituted C 1~6 Alkyl groups, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 It may be optionally substituted with an alkoxy group or a cyano group.

[0060] In the present invention, preferably, 1~6 Alkyl group, C 3~6 Cycloalkyl groups, C 1~6 The alkoxy group may further be optionally substituted with one or more F atoms.

[0061] More preferably, the R 1b is selected from a substituted or unsubstituted phenyl group, a thienyl group, or a thiazolyl group.

[0062] The phenyl, thienyl and thiazolyl groups may each be substituted with one or more halogen atoms, substituted or unsubstituted C 1~6 Alkyl groups, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 It may be optionally substituted with an alkoxy group, a cyano group, a hydroxyl group, or an amino group.

[0063] C above 1~6 The alkyl group is preferably a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group or a tert-butyl group.

[0064] C above 1~6 The alkoxy group is preferably a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group or a pentyloxy group.

[0065] C above 3~6 The cycloalkyl group is preferably a cyclopropyl group, a cyclobutyl group, a cyclopentyl group or a cyclohexyl group.

[0066] C above 1~6 Alkyl group, C 1~6 Alkoxy group, C 3~6 The cycloalkyl group may further be optionally substituted with 1 to 3 fluorine atoms.

[0067] In the present invention, in the above formula IIc, ring A is preferably a 5- to 6-membered monocyclic heterocyclic group or a 7- to 10-membered spiro heterocyclic group.

[0068] In the present invention, preferably, in the above formula IIc, ring A and / or R1 and R2 together with the atom adjacent to the atom to which they are bonded form a 4- to 10-membered ring, preferably a 5- or 6-membered monocyclic ring.

[0069] In the present invention, the ring A in the above formula IIc is preferably a 5- or 6-membered monocyclic heterocyclic group, more preferably a tetrahydropyrrole ring.

[0070] The 5- or 6-membered monocyclic heterocyclic group may contain one or more of halogen, C 1~3 Alkyl group, C 3~6 It may be optionally substituted with a cycloalkyl group.

[0071] Specifically, it may be optionally substituted with one or more of fluorine, chlorine, bromine, methyl group, ethyl group, propyl group, isopropyl group, cyclopropyl group, cyclobutyl group, cyclopentyl group, or cyclohexyl group.

[0072] The range of selection of R5 in the above formulae IIa to IIc is the same as above, but will not be detailed here.

[0073] In the present invention, preferably, R2 is H, wherein R3 is H; R4 is fluorine, chlorine, bromine or iodine, and further is ortho-difluoro, ortho-dichloro or ortho-dibromo at the L position; wherein R6 is H; wherein L is —O—; The X is O.

[0074] In the present invention, the 2-pyridone derivative preferably has any one of the following structures:

[0075] [ka]

[0076] [ka]

[0077] [ka]

[0078] Some examples of compounds according to the present invention can be realized by the following reaction schemes.

[0079] [ka]

[0080] The present invention further provides the use of the above 2-pyridone derivatives in the preparation of medicaments for preventing, treating and / or alleviating diseases regulated by thyroid hormone analogues.

[0081] In the present invention, preferably, the diseases regulated by thyroid hormone analogs include one or more of obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease (NASH), atherosclerosis, cardiovascular disease, hypothyroidism, and thyroid cancer.

[0082] The present invention further provides a pharmaceutical preparation containing the above-mentioned 2-pyridone derivative and a pharmaceutically acceptable excipient. In the present invention, the dosage form of the pharmaceutical preparation can be a tablet, hard capsule, soft capsule, dry suspension, drop pill or micropellet.

[0083] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes examples in which the event or circumstance occurs and examples in which it does not occur. For example, "an optionally substituted alkyl group" includes "alkyl group" and "substituted alkyl group" as defined herein. Those skilled in the art should understand that any group containing one or more substituents unintentionally introduces any substitution or forms of substitution that are sterically infeasible, synthetically infeasible, and / or inherently unstable. The term "alkyl group" includes straight and branched chain alkyl groups having the specified number of carbon atoms (generally, 1 to 20 carbon atoms, e.g., 1 to 8 carbon atoms, 1 to 6 carbon atoms). For example, a C1-C6 alkyl group includes straight and branched chain alkyl groups having 1 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, and the like. An alkylene group is another subset of alkyl groups, meaning that the same residue as an alkyl group has two points of attachment. An alkylene group typically has 2 to 20 carbon atoms, e.g., 2 to 8 carbon atoms, 2 to 6 carbon atoms. When an alkyl residue having a specific number of carbon atoms is named, all geometric isomers having that number of carbon atoms are intended to be included, for example, "butyl" includes n-butyl, sec-butyl, isobutyl, and tert-butyl, and "propyl" includes n-propyl and isopropyl. "Lower alkyl" means an alkyl group having 1 to 4 carbon atoms.

[0084] An "alkenyl group" refers to a straight- or branched-chain hydrocarbon group having a specified number of carbon atoms (generally 1 to 8 carbon atoms, e.g., 2 to 4 carbon atoms) and at least one, preferably 1 to 2, sites of c(>C=C<) unsaturation. Examples of such groups include, for example, vinyl, allyl, and but-3-en-1-yl. The term includes cis and trans isomers or mixtures of these isomers. A "lower alkenyl group" refers to an alkenyl group having 1 to 4 carbon atoms and can be represented by a C2-C4 alkenyl group. "Cycloalkyl group" means a non-aromatic, partially saturated, or fully saturated carbocyclic ring having a specified number of ring carbon atoms (e.g., 3 to 10, or 3 to 8, or 3 to 6 ring carbon atoms). Cycloalkyl groups can be monocyclic or polycyclic (e.g., bicyclic, tricyclic). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, and cyclohexyl groups, as well as bridged ring groups and cage ring groups (e.g., dicyclo[2.2.2]octane). Lower cycloalkanes generally refer to 3 to 6 monocyclic rings.

[0085] An "aryl group" refers to an aromatic carbocyclic ring having a specified number of carbon atoms in the ring (e.g., 6 to 12 or 6 to 10 carbon atoms). Aryl groups can be monocyclic or polycyclic (e.g., bicyclic, tricyclic). In some cases, both rings of a polycyclic aryl group are aromatic (e.g., a naphthyl group). In other cases, a polycyclic aryl group can contain a non-aromatic ring (e.g., a cycloalkyl group, a cycloalkenyl group, a heterocycloalkyl group, or a heterocycloalkenyl group) fused to an aromatic ring, so long as the ring is connected to the parent structure through an atom in the aromatic ring. Thus, 1,2,3,4-tetrahydronaphthalen-5-yl (where the moiety is connected to the parent structure through an aromatic carbon atom) is recognized as an aryl group, but 1,2,3,4-tetrahydronaphthalen-1-yl (where the moiety is connected to the parent structure through a non-aromatic carbon atom) is not recognized as an aryl group. Similarly, 1,2,3,4-tetrahydroquinolin-8-yl (wherein the moiety is attached to the parent structure through an aromatic carbon atom) is recognized as an aryl group, while 1,2,3,4-tetrahydroquinolin-1-yl (wherein the moiety is attached to the parent structure through a non-aromatic carbon atom) is not recognized as an aryl group. However, the term "aryl group" is meant to not include or overlap with "heteroaryl groups" as defined herein, regardless of the point of attachment (e.g., quinolin-5-yl and quinolin-2-yl are both heteroaryl groups). In some cases, the aryl group is a phenyl group or a naphthyl group. In other cases, the aryl group is a phenyl group. Other examples of aryl groups containing an aromatic carbocyclic ring fused to a non-aromatic ring are described below.

[0086] "Carboxy" or "carboxyl" means --COOH or a salt thereof. A "heteroaryl group" refers to an aromatic ring containing the specified number of ring atoms (e.g., a 5- to 12- or 5- to 10-membered heteroaryl group), wherein the ring atoms consist of one or more heteroatoms (e.g., 1, 2, 3, or 4 heteroatoms) selected from N, O, and S, and the remaining ring atoms are carbon. A 5-membered heteroaryl group is a heteroaryl group having 5 ring atoms. A 6-membered heteroaryl group is a heteroaryl group having 6 ring atoms. In some embodiments, the total number of S and O atoms in a heteroaryl group does not exceed 2. In some embodiments, the total number of S and O atoms in a heteroaryl group does not exceed 1. Unless otherwise specified, a heteroaryl group can be attached to the parent structure through a carbon or nitrogen atom, valence permitting. For example, "pyridine group" includes 2-pyridine, 3-pyridine, and 4-pyridine groups, and "pyrrolyl group" includes 1-pyrrolyl, 2-pyrrolyl, and 3-pyrrolyl groups. When nitrogen is present in a heteroaryl ring, said nitrogen can be present in an oxidized state (i.e., N-O-) when the nature of the adjacent atoms and groups permits. Additionally, when sulfur is present in a heteroaryl ring, said sulfur can be present in an oxidized state (i.e., S-O- or SO2) when the nature of the adjacent atoms and groups permits. Heteroaryl groups can be monocyclic or polycyclic (e.g., bicyclic, tricyclic).

[0087] In some cases, the heteroaryl group is monocyclic. Examples include pyrrole, pyrazole, imidazole, triazole (e.g., 1,2,3-triazole, 1,2,4-triazole, 1,2,4-triazole), tetrazole, furan, isoxazole, oxazole, oxadiazole (e.g., 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole), thiophene, isothiazole, thiazole, thiadiazole (e.g., 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole), pyridine, pyridazine, pyrimidine, pyrazine, triazine (e.g., 1,2,4-triazine, 1,3,5-triazine), and tetrazine. In other cases, polycyclic heteroaryl groups can contain non-aromatic rings (e.g., cycloalkyl groups, cycloalkenyl groups, heterocycloalkyl groups, and heterocycloalkenyl groups) fused to the heteroaryl ring, as long as they are attached to the parent structure through an atom in the aromatic ring. For example, 4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl (where the moiety is attached to the parent structure through an aromatic carbon atom) is recognized as a heteroaryl group, while 4,5,6,7-tetrahydrobenzo[d]thiazol-5-yl (where the moiety is attached to the parent structure through a non-aromatic carbon atom) is not recognized as a heteroaryl group. Examples of polycyclic heteroaryl groups consisting of heteroaryl rings fused to non-aromatic rings are described below. "Heterocycloalkyl group" means a non-aromatic partially saturated or fully saturated ring having the specified number of ring atoms (e.g., a 3- to 10- or 3- to 7-membered heterocycloalkyl group), wherein the ring atoms consist of one or more heteroatoms (e.g., 1, 2, 3, or 4 heteroatoms) selected from N, O, and S, and the remaining ring atoms are carbon. A 5-membered heterocycloalkyl group is a heterocycloalkyl group having 5 ring atoms. A 6-membered heterocycloalkyl group is a heterocycloalkyl group having 6 ring atoms. A heterocycloalkyl group can be monocyclic or polycyclic (e.g., bicyclic, tricyclic). Examples of heterocycloalkyl groups include oxetanyl, aziridine, azetidine, pyrrolidine, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, and thiomorpholinyl groups. When nitrogen is present in a heterocycloalkyl ring, said nitrogen can be present in an oxidized state (i.e., N+-O-), when the nature of the adjacent atoms and groups permits. Examples include piperidinyl-N-oxide and morpholinyl-N-oxide. Furthermore, when sulfur is present in a heterocycloalkyl ring, said sulfur can be present in an oxidized state (i.e., S+-O- or -SO2-), when the nature of the adjacent atoms and groups permits. Examples include thiomorpholine S-oxide and thiomorpholine S,S-dioxide. Furthermore, one ring in a polycyclic heterocycloalkyl group can be aromatic (e.g., an aryl or heteroaryl group), so long as the polycyclic heterocycloalkyl group is attached to the parent structure through a non-aromatic carbon or nitrogen atom. For example, 1,2,3,4-tetrahydroquinolin-1-yl (wherein the moiety is attached to the parent structure through a non-aromatic nitrogen atom) is recognized as a heterocycloalkyl group, while 1,2,3,4-tetrahydroquinolin-8-yl (wherein the moiety is attached to the parent structure through an aromatic carbon atom) is not recognized as a heterocycloalkyl group. Examples of polycyclic heterocycloalkyl groups consisting of heterocycloalkyl groups fused with an aromatic ring are described below.

[0088] "Alkoxy" means an alkyl group of the specified number of carbon atoms connected through an oxygen bridge, including, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentyloxy, 2-pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, 2-hexyloxy, 3-hexyloxy, 3-methylpentyloxy, and the like. Alkoxy is also intended to include cycloalkyl groups, as defined above, connected through an oxygen bridge. Alkoxy groups typically have 1 to 6 carbon atoms connected through an oxygen bridge. "Lower alkoxy" means an alkoxy group having 1 to 4 carbon atoms. The term "halogenated" includes fluorinated, chlorinated, brominated and iodinated, and the term "halogen" includes fluorine, chlorine, bromine and iodine.

[0089] As used herein, the term "substituted" means that any one or more hydrogens on the specified atom or group may be selectively replaced with the specified group, provided that the normal valence of the specified atom is not exceeded. When a substituent is oxo (i.e., =0), two hydrogens on said atom are replaced. Combinations of substituents and / or variables are permissible so long as such combinations produce stable compounds or useful synthetic intermediates. A stable compound or stable structure is intended to imply sufficient stability to survive isolation from a reaction mixture and thereafter be prepared as a reagent having at least practical utility. Unless otherwise indicated, substituents are named on the core structure. For example, when a (cycloalkyl)alkyl group is listed as a possible substituent, it should be understood that the point of attachment of the substituent to the core structure is at the alkyl portion. Pharmaceutically acceptable salts include, but are not limited to, salts with inorganic acids such as hydrochloride, phosphate, diphosphate, hydrobromide, sulfate, sulfinate, nitrate, and similar salts; salts with organic acids such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, and alkanoate salts such as acetate, HOOC-(CH)-COOH (where n is 0-4), and similar salts. Similarly, pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium.

[0090] Also, if a compound described herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, can be prepared by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to conventional methods for preparing acid addition salts from basic compounds. Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts. As used herein, the terms "group," "residue," or "fragment" are synonymous and are meant to refer to a functional group or molecular fragment that can be linked to a bond or other molecular fragment.

[0091] The term "therapeutically effective amount" or "effective amount" refers to an amount that, when administered to a human or non-human subject, effectively provides a therapeutic benefit, such as amelioration of symptoms, delaying disease progression, or preventing disease, or inhibits actin-bundling protein activity in vitro or in vivo. For example, a therapeutically effective amount would alleviate symptoms of a disease in response to inhibition of actin-bundling protein activity. By "amount" is meant an amount that may be sufficient to By "treatment" is meant any treatment for a disease in a patient, including: a) prevent disease, i.e., prevent the development of clinical symptoms that cause the disease; b) Suppression of disease progression; c) slowing or preventing the development of clinical symptoms, and / or d) to be disease-relieving, i.e., to result in the disappearance of clinical symptoms.

[0092] "Subject" or "patient" means an animal, such as a mammal, who has been or will be the object of treatment, observation, or experiment. The methods described herein may be useful for both human therapy and veterinary applications. In some embodiments, the subject is a mammal, and in some embodiments, the subject is human. The compounds described herein can be prepared into pharmaceutical compositions and administered to a mammalian host (e.g., a human patient) in a variety of forms appropriate for the selected route of administration, including oral or parenteral, intravenous, intramuscular, topical, transdermal, intrathecal, intraocular, intranasal, intraperitoneal, or subcutaneous routes.

[0093] The compounds described herein can be administered systemically, for example, orally or intravenously in combination with a pharmaceutically acceptable vehicle (e.g., an inert diluent or an assimilable edible carrier). They can be encapsulated in hard or soft gelatin capsules, compressed into tablets, or mixed directly with the food of the patient's diet. For oral therapeutic administration, the active compound can be combined with one or more excipients and used in the form of ingestible tablets, swallowed tablets, dragees, capsules, elixirs, suspensions, syrups, wafers, and the like. The starting materials used in the reactions below are generally known compounds or can be prepared by known procedures or obvious modifications thereof.

[0094] Where appropriate, conventional techniques such as filtration, crystallization, evaporation, distillation, and chromatography can be used to separate and purify the various starting materials, intermediates, and compounds described herein. Characterization of these compounds can be carried out using conventional methods such as melting point, mass spectrometry, nuclear magnetic resonance, and other spectroscopic analyses. The present disclosure is not limited by the specific embodiments described herein, but rather, these specific embodiments are intended to be illustrative of various aspects. It will be apparent to those skilled in the art that many modifications and variations can be made without departing from the spirit and scope of the present disclosure. Functionally equivalent compositions, devices, and methods within the scope of the present disclosure, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing description. Such modifications and variations are intended to be encompassed within the scope of the appended claims. The present disclosure is limited only by the scope of the appended claims and the full scope of equivalents afforded by such claims. It is to be understood that the present disclosure is not limited to particular methods, reagents, compounds, compositions, or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is used only for the purpose of describing particular embodiments, and is not intended to be limiting.

[0095] Furthermore, features or aspects of the present disclosure have been described in terms of Markush groups, and those skilled in the art will recognize that the present disclosure can also be described in terms of any individual member or subgroup of members of the Markush group. While several embodiments have been illustrated and described, it should be understood that changes and modifications can be made therein in accordance with common skill in the art without departing from the technology defined in its broader aspects in the following claims. [Effects of the Invention]

[0096] Compared with the prior art, the present invention provides 2-pyridone derivatives having the structure represented by Formula I or stereoisomers or pharmaceutically acceptable salts thereof. Activity experiments have shown that the 2-pyridone derivatives provided by the present invention have high activity and selectivity and can be used to treat diseases related to thyroid hormone receptors. DETAILED DESCRIPTION OF THE INVENTION

[0097] In order to further illustrate the present invention, the 2-pyridone derivatives provided by the present invention, their preparation methods, and pharmaceutical applications will be described in detail below in conjunction with examples. [Example]

[0098] Example 1 2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0099] [ka]

[0100] First step 5-(2,6-dichloro-4-nitrophenoxy)-2-methoxypyridine 6-Methoxypyridin-3-ol 1a (6.3 g, 50.4 mmol) was dissolved in 80 mL of N,N-dimethylformamide, and 3,5-dichloro-4-fluoroaniline (13.8 g, 65.5 mmol) and potassium carbonate (20.8 g, 151.0 mmol) were added. The mixture was then reacted at 24 °C for 16 hours. 70 mL of water was added to the reaction mixture until a large amount of white solid precipitated. The mixture was then filtered, and the filter cake was washed with water once or twice. The filter cake was then dissolved in isopropanol and concentrated. This process was repeated twice, and the solvent was removed by evaporation under reduced pressure to give 5-(2,6-dichloro-4-nitrophenoxy)-2-methoxypyridine 1b (15.0 g, pale yellow solid) in 94.5% yield. MS m / z (ESI): 315.00 [M+1] + . Second step 5-(2,6-dichloro-4-nitrophenoxy)-2-carbonylpyridine 5-(2,6-Dichloro-4-nitrophenoxy)-2-methoxypyridine 1b (15.0 g, 47.60 mmol) was dissolved in 30 mL of a 1:1 mixture of hydrobromic acid and acetic acid. The mixture was heated to 100 °C and reacted under nitrogen gas protection for 4 hours. The solvent was evaporated under reduced pressure until a large amount of white solid precipitated. The mixture was filtered, and the filter cake was dissolved in isopropanol and concentrated. This process was repeated two or three times to give 5-(2,6-dichloro-4-nitrophenoxy)-2-hydroxypyridine 1c (13.0 g, pale yellow solid) in 90.7% yield. MS m / z (ESI): 300.95 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 8.52 (s,2H),7.44 (d,J = 8.0 Hz,1H),7.27 (s,1H),6.49(d,J = 8.0 Hz,1H). Third step 5-(2,6-dichloro-4-nitrophenoxy)-1-isopropyl-2-hydroxypyridine 5-(2,6-Dichloro-4-nitrophenoxy)-2-hydroxypyridine 1c (2.5 g, 8.3 mmol) was dissolved in 30 mL of ethylene glycol dimethyl ether, and then potassium tert-butoxide (932.0 mg, 8.3 mmol) was added and the mixture was stirred at room temperature for 40 minutes. Potassium carbonate (803.0 mg, 5.81 mmol) and isopropyl iodide (2.5 mL, 24.91 mmol) were then added. The mixture was heated to 100°C and allowed to react at that temperature for 4 hours. The reaction mixture was partially evaporated under reduced pressure, 30 mL of water was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to give 5-(2,6-dichloro-4-nitrophenoxy)-1-isopropyl-2-hydroxypyridine 1d (1.1 g, yellow solid) in 38.6% yield. MS m / z (ESI): 343.00 [M+1] + . 1 H NMR (400 MHz,CDCl3) δ 8.31 (s,2H),7.11 (dd,J = 8.0,4.0 Hz,1H),7.05 (d,J = 4.0 Hz,1H),6.63(d,J = 8.0 Hz,1H),5.30-5.20 (m,1H),1.33(d,J = 8.0Hz,6H). Fourth step 5-(4-amino-2,6-dichlorophenoxy)-1-isopropyl-2-hydroxypyridine 5-(2,6-Dichloro-4-nitrophenoxy)-1-isopropyl-2-hydroxypyridine 1d (1.1 g, 3.2 mmol) was dissolved in 10 mL of methanol, followed by the addition of saturated aqueous ammonium chloride (1 mL) and iron powder (895.0 mg, 16 mmol). The mixture was then reacted at 100 °C for 4 hours. The reaction mixture was filtered, and the filtrate was evaporated on a rotary evaporator. 30 mL of water was added, followed by extraction with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give 5-(4-amino-2,6-dichlorophenoxy)-1-isopropyl-2-hydroxypyridine 1e (760.0 mg, gray solid) in 75.7% yield. MS m / z (ESI): 313.05 [M+1] + . Fifth step (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetylcarbamic acid ethyl ester 5-(4-amino-2,6-dichlorophenoxy)-1-isopropyl-2-hydroxypyridine 1e (760.0 mg, 2.43 mmol) was dissolved in 6N aqueous hydrochloric acid, the temperature was lowered to 0°C, and then aqueous sodium nitrite solution (251.1 mg, 3.64 mmol, 1 mL) was added to the reaction mixture and allowed to react at 0°C for 30 minutes. N-cyanoacetylurethane (568.3 mg, 3.64 mmol) was then dissolved in 3 mL of water, the temperature was lowered to 0°C, pyridine (5 mL) was added, and the previous reaction solution was slowly added dropwise to the next reaction solution, followed by reaction at 0°C for 30 minutes. 15 mL of water was added to the reaction mixture, and a large amount of solid precipitated. The mixture was filtered, and the filter cake was dissolved in isopropanol and concentrated. This process was repeated two or three times to obtain crude (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetylcarbamate 1f (1.0 g, reddish-brown solid). MS m / z (ESI): 482.05 [M+1] + . Sixth step 2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetylcarbamate ethyl ester 1f The crude product (1.0 g) was dissolved in N,N-dimethylacetamide (15 mL), sodium acetate (512.3 mg, 2.08 mmol) was added, and the mixture was allowed to react at 120 °C for 3 hours. 30 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give (3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 1 (650.0 mg, red solid) in a two-step yield of 61.6%. MS m / z (ESI): 434.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 7.78 (s,2H),7.58 (d,J = 4.0 Hz,1H),7.23 (dd,J = 8.0,4.0 Hz,1H),6.38 (d,J = 8.0 Hz,1H),5.10 - 4.93 (m,1H),1.27 (d,J = 8.0 Hz,8H).

[0101] Example 2 2-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1H-1,2,4-triazine-6-carbonitrile

[0102] [ka]

[0103] First step 5-(4-amino-2,6-dichlorophenoxy)-2-carbonylpyridine 5-(4-nitro-2,6-dichlorophenoxy)-2-carbonylpyridine 1c (400.0 mg, 1.33 mmol) was dissolved in 6 mL of methanol, and iron powder (222.5 mg, 3.99 mmol) and 1 mL of saturated aqueous ammonium chloride solution were added. The mixture was then reacted at 85°C for 6 hours. The iron powder was removed by magnetic suction, and the reaction mixture was evaporated on a rotary evaporator. The mixture was extracted three times with 20 mL of ethyl acetate and 15 mL of water, washed once more with saturated brine, dried over anhydrous sodium sulfate, filtered, and the organic phase was evaporated on a rotary evaporator. The mixture was purified by flash silica gel column chromatography to give 5-(4-amino-2,6-dichlorophenoxy)-2-carbonylpyridine 2a (100.0 mg, brown solid) in 27.8% yield. MS m / z (ESI): 271.00 [M+1] + . Second step Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazino)acetyl)carbamate 5-(4-Amino-2,6-dichlorophenoxy)-2-carbonylpyridine 2a (100.0 mg, 0.37 mmol) was dissolved in 4 mL of 6N aqueous hydrochloric acid, the temperature was lowered to 0°C, and then 0.5 mL of aqueous sodium nitrite (38.1 mg, 0.55 mmol) was slowly added dropwise. The reaction mixture was then stirred for 20 minutes. Next, N-cyanoacetylurethane (86.4 mg, 0.55 mmol) was dissolved in 3 mL of water, the temperature was lowered to 0°C, and then 2 mL of pyridine was added and stirred at 0°C for 10 minutes. Next, the latter reaction mixture was slowly added dropwise to the former reaction mixture and allowed to react at 0°C for 30 minutes. 20 mL of water was added to the reaction mixture, and a large amount of solid precipitated. The mixture was filtered, and the filter cake was dissolved in absolute ethanol and concentrated. This process was repeated two or three times to obtain ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazino)acetyl)carbamate 2b (100.0 mg, red solid) in 61.8% yield. MS m / z (ESI): 437.95 [M+1] + . Third step 2-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazino)acetyl)carbamate 2b (100.0 mg, 0.23 mmol) was dissolved in 5 mL of N,N-dimethylacetamide, and then sodium acetate (74.9 mg, 0.91 mmol) was added. The mixture was then heated to 120°C and reacted at that temperature for 4 hours. 20 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. 2-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 2 (4.99 mg, white solid) was obtained in a 5.6% yield. MS m / z (ESI): 391.95 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.29 (s,1H),7.78 (s,2H),7.38 (dd,J = 9.6 Hz,3.2 Hz,1H),7.21 (s,1H),6.46 (d,J = 9.6 Hz,1H).

[0104] Example 3 2-(3,5-dichloro-4-[(1-cyclobutyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0105] [ka]

[0106] Using the method of Example 1, substituting bromocyclobutane for isopropyl iodide, the title product 2-(3,5-dichloro-4-[(1-cyclobutyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 3 (35.0 mg, white solid) was prepared. MS m / z (ESI): 446.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 7.79 (s,2H),7.62 (d,J = 3.2 Hz,1H),7.25 (dd,J = 10.0,3.2 Hz,1H),6.36 (d,J = 10.0 Hz,1H),5.07-4.95 (m,1H),2.30-2.21 (m,4H),1.79-1.67 (m,2H).

[0107] Example 4 2-(3,5-dichloro-4-[(1-cyclobutyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0108] [ka]

[0109] Using the method of Example 1, substituting 2-chlorocyclopentanone for isopropyl iodide, the title product 2-(3,5-dichloro-4-((6-oxo-1-(2-oxocyclopentyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 4 (20.0 mg, white solid, 23.03% yield) was prepared. MS m / z (ESI): 471.95 [M+1] + . 1H NMR (400 MHz,DMSO-d6) δ 13.28 (br s,1H),7.78 (s,2H),7.47 (d,J = 4.0 Hz,1H),7.43 (d,J = 4.0 Hz,1H),6.43 (d,J = 10.0 Hz,1H),4.59-4.54 (m,1H),2.56-2.21 (m,5H),1.81-1.69 (m,1H).

[0110] Example 5 2-(3,5-dichloro-4-((1-(cyclopentylmethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0111] [ka]

[0112] Using the method of Example 1, substituting (bromomethyl)cyclopentane for isopropyl iodide, the title product 2-(3,5-dichloro-4-((1-(cyclopentylmethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 5 (16.0 mg, white solid, 41.29% yield) was prepared. MS m / z (ESI): 471.95 [M-1] - . 1 H NMR (400 MHz,DMSO-d6) δ 13.27 (br s,1H),7.78 (s,2H),7.43-7.37 (m,2H),6.42 (d,J = 8.0 Hz,1H),3.78 (d,J = 8.0 Hz,2H),2.33-2.20 (m,1H),1.76-1.30 (m,6H),1.19-1.10 (m,2H).

[0113] Example 6 2-(3,5-dichloro-4-[(1-(2-methylpropyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0114] [ka]

[0115] Using the method of Example 1, substituting 1-iodo-2-methylpropane for isopropyl iodide, the title product 2-(3,5-dichloro-4-[(1-(2-methylpropyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 6 (70.0 mg, white solid) was prepared in 77.8% yield. MS m / z (ESI): 448.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.28 (s,1H),7.78 (s,2H),7.43 (dd,J = 10.0,3.6 Hz,1H),7.38 (d,J = 3.2 Hz,1H),6.44 (d,J = 10.0 Hz,1H),3.66 (d,J = 7.2 Hz,2H),2.08 - 1.94 (m,1H),0.81 (d,J = 6.8 Hz,6H).

[0116] Example 7 2-(3,5-dichloro-4-((6-oxo-1-(pentan-3-yl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0117] [ka]

[0118] Using the method of Example 1, substituting 3-bromopentane for isopropyl iodide, the title product 2-(3,5-dichloro-4-((6-oxo-1-(pentan-3-yl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 7 (70 mg, pale yellow solid, 29.76% yield) was prepared. MS m / z (ESI): 460.00 [M-1] - . 1 H NMR (400 MHz,DMSO-d6) δ 13.29 (s,1H),7.77 (s,2H),7.39 (s,1H),7.26 (dd,J = 10.0,3.6 Hz,1H),6.41 (d,J = 10.0 Hz,1H),4.69 (m,1H),1.71-1.62 (m,4H),0.70 (t,J = 8.0 Hz,6H).

[0119] Example 8 2-(3,5-dichloro-4-((1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0120] [ka]

[0121] Using the method of Example 1, substituting 1-bromo-2-methoxyethane for isopropyl iodide, the title product 2-(3,5-dichloro-4-((1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 8 (257.0 mg, white solid, 15.24% yield). MS m / z (ESI): 449.95 [M+1] + .

[0122] Example 9 2-(3,5-dichloro-4-((1-cyclohexyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0123] [ka]

[0124] Using the method described in Example 1, isopropyl iodide was converted to cyclohexyl p-toluenesulfonate to give the title product, 2-(3,5-dichloro-4-((1-cyclohexyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 9 (12.0 mg, white solid) in 83.8% yield. MS m / z (ESI): 475.30 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.28 (s,1H),7.79 (s,2H),7.55 (d,J = 4.0 Hz,1H),7.24 (dd,J = 8.0,4.0 Hz,1H),6.40 (d,J = 8.0 Hz,1H),4.71-4.56 (m,1H),1.86-1.76 (m,2H),1.73-1.54 (m,5H),1.44-1.28 (m,2H),1.27-1.14 (m,1H).

[0125] Example 10 2-(3,5-dichloro-4-((1-cyclopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0126] [ka]

[0127] First step 1-Cyclopropyl-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 5-(2,6-Dichloro-4-nitrophenoxy)-2-hydroxypyridine 1c (0.6 g, 1.99 mmol) was dissolved in 10 mL of toluene, and cyclopropyl borate (342.0 mg, 3.99 mmol), copper acetate (361.9 mg, 1.99 mmol), pyridine (0.8 mL, 9.96 mmol), and di(trimethylsilyl)aminosodium (365.0 mg, 1.99 mmol) were added, followed by reaction at 100°C for 4 hours. The reaction was quenched with water and concentrated. 30 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give 1-cyclopropyl-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 10a (265.0 mg, yellow solid) in 31.2% yield. MS m / z (ESI): 341.00 [M+1] + . Second step 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopropylpyridin-2(1H)-one 1-Cyclopropyl-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 10a (265.0 mg, 0.78 mmol) was dissolved in 4 mL of methanol, followed by the addition of saturated aqueous ammonium chloride (0.5 mL) and iron powder (173.5 mg, 3.11 mmol). The mixture was then reacted at 100 °C for 4 hours. After filtration, the filtrate was evaporated on a rotary evaporator, 15 mL of water was added, and extracted with ethyl acetate (30 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopropylpyridin-2(1H)-one 10b (150.0 mg, brown solid) in 77.6% yield. MS m / z (ESI): 311.00 [M+1] + . 1H NMR (400 MHz,DMSO-d6) δ 7.20 (dd,J = 12.0 Hz,4.0 Hz,1H),6.99 (d,J = 4.0 Hz,1H),6.68 (s,2H),6.36 (d,J = 12.0 Hz,1H),5.69 (s,2H),3.31 - 3.21 (m,1H),0.97-0.94 (m,2H),0.75-0.72 (m,2H). Third step Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazone)acetyl)carbamate 5-(4-Amino-2,6-dichlorophenoxy)-1-cyclopropylpyridin-2(1H)-one 10b (150.0 mg, 0.482 mmol) was dissolved in 4 mL of 6N aqueous hydrochloric acid, the temperature was lowered to 0° C., and then a solution of sodium nitrite (49.8 mg, 0.723 mmol) dissolved in 0.5 mL of water was added and reacted at 0° C. for 30 minutes. N-Cyanoacetylurethane (112.9 mg, 0.723 mmol) was dissolved in 3 mL of water, the temperature was lowered to 0° C., and pyridine (2 mL) was added thereto. The previous reaction solution was slowly added dropwise to the next reaction solution, and then the reaction was continued at 0° C. for 30 minutes. 15 mL of water was added to the reaction mixture, and a large amount of solid precipitated. The mixture was filtered, and the filter cake was dissolved in isopropanol and concentrated. This process was repeated two or three times to obtain crude (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazone)acetyl)carbamate ethyl 10c (140.0 mg, reddish-brown solid). MS m / z (ESI): 478.05 [M+1] + . Fourth step 2-(3,5-dichloro-4-((1-cyclopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile Ethyl ((E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazone)acetyl)carbamate 10c The crude product (140.0 mg, 0.29 mmol) was dissolved in N,N-dimethylacetamide (5 mL), potassium acetate (86.1 mg, 0.87 mmol) was added, and the mixture was then reacted at 120 °C for 3 hours. 20 mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was isolated by preparative HPLC to give 2-(3,5-dichloro-4-((1-cyclopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 10 (37.7 mg, white solid) in a 30.0% yield. MS m / z (ESI): 432.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.29 (s,1H),7.78 (s,2H),7.31-7.28 (m,2H),6.38 (d,J = 12.0 Hz,1H),3.33 - 3.24 (m,1H),0.99-0.93 (m,2H),0.83-0.80 (m,2H).

[0128] Example 11

[0129] [ka]

[0130] First step 1-(cyclopentyl-1-en-1-yl)-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 1c (2.00 g, 6.60 mmol) was dissolved in 20 mL of toluene, followed by pyridine (2.61 g, 33.00 mmol), copper acetate (1.20 g, 6.60 mmol), cyclopentyl-1-en-1-ylboronic acid (2.96 g, 26.40 mmol), and di(trimethylsilyl)aminosodium (1.22 g, 6.60 mmol) in that order. The mixture was reacted at 100 ° C. for 8 hours, the solvent was removed, and the resulting mixture was purified by flash silica gel column chromatography to give 1-(cyclopentyl-1-en-1-yl)-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 11a (0.70 g, white solid) in a yield of 28.1%. MS m / z (ESI): 367.00 [M+1] + . Second step 5-(4-amino-2,6-dichlorophenoxy)-1-(cyclopentyl-1-en-1-yl)pyridin-2(1H)-one 1-(Cyclopentyl-1-en-1-yl)-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 11a (200.0 mg, 0.54 mmol) and iron powder (152.0 mg, 2.73 mmol) were added to 10.0 mL of ethanol, and 2.0 mL of saturated aqueous ammonium chloride solution was added. The mixture was heated to 100 °C and reacted for 4 hours. The solvent was removed, and the residue was purified by flash silica gel column chromatography to give 5-(4-amino-2,6-dichlorophenoxy)-1-(cyclopentyl-1-en-1-yl)pyridin-2(1H)-one 11b (180.0 mg, white solid) in 98.1% yield. MS m / z (ESI): 337.05 [M+1] + . Third step (E) (2-cyano-2-(2-(3,5-dichloro-4-((1-(cyclopentyl-1-en-1-yl)-6-oxy-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazino)acetyl)carbamic acid ethyl ester 5-(4-amino-2,6-dichlorophenoxy)-1-(cyclopentyl-1-en-1-yl)pyridin-2(1H)-one 11b (180.0 mg, 0.53 mmol) was dissolved in 8.0 mL of acetic acid and 2.0 mL of water, the temperature was lowered to 0°C, 1.0 mL of concentrated hydrochloric acid was added, 2.0 mL of an aqueous solution of sodium nitrite (44.0 mg, 0.63 mmol) was slowly added dropwise, and the mixture was stirred for 10 minutes. Sodium acetate (23.5 mg, 0.34 mmol) was then added. mol) and N-cyanoacetylurethane (165.3 mg, 1.06 mmol) were added, the ice bath was removed, the mixture was warmed to room temperature, and the mixture was allowed to react for 12 hours. 15 mL of water was added, and a solid was formed. The solid was filtered and dried to give ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-(cyclopentyl-1-en-1-yl)-6-oxy-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazino)acetyl)carbamate 11c (179.0 mg, yellow solid) in a yield of 67.3%. The crude product was used directly in the next step. MS m / z (ESI): 504.05 [M+1] + . Fourth step 2-(3,5-dichloro-4-((1-(cyclopentyl-1-en-1-yl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile The crude (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-(cyclopentyl-1-en-1-yl)-6-oxy-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazino)acetyl)carbamate 11c (179.0 mg, 0.35 mmol) was dissolved in N,N-dimethylacetamide (5.0 mL), potassium acetate (104.0 mg, 1.06 mmol) was added, and the mixture was reacted at 120° C. for 3 hours. The solvent was removed, and the resulting product was purified by preparative HPLC to give 2-(3,5-dichloro-4-[(5-cyclopropyl-6-oxo-1-(propyl-2-yl)-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 11 (22.0 mg, white solid) in a 13.1% yield. MS m / z (ESI): 458.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.29 (s,1H),7.78 (s,2H),7.41 (dd,J = 10.0,3.2 Hz,1H),7.27 (d,J = 3.2 Hz,1H),6.44 (d,J = 10.0 Hz,1H),6.00-5.96 (s,1H),2.70-2.59 (m,2H),2.43-2.38 (m,2H),2.01-1.89 (m,2H).

[0131] Example 12

[0132] [ka]

[0133] First step 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopentylpyridin-2(1H)-one 1-(Cyclopentyl-1-en-1-yl)-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 11a (500.0 mg, 0.54 mmol) was dissolved in ethyl acetate (10.0 mL), and palladium on carbon (Pd 10%) (50.0 mg) was added. The mixture was reacted under a hydrogen atmosphere (15 psi) at room temperature for 12 hours. The mixture was filtered, the solvent was removed, and the residue was purified by flash silica gel column chromatography to give 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopentylpyridin-2(1H)-one 12a (301.0 mg, white solid) in 60.1% yield. MS m / z (ESI): 339.05 [M+1] + . Second step Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-oxy)phenyl)hydrazone)acetyl)carbamate 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopentylpyridin-2(1H)-one 12a (180.0 mg, 0.53 mmol) was dissolved in 8.0 mL of acetic acid and 2.0 mL of water, the temperature was lowered to zero, 1.0 mL of concentrated hydrochloric acid was added, 2.0 mL of aqueous sodium nitrite (44.0 mg, 0.63 mmol) was slowly added dropwise, and the mixture was stirred for 10 minutes. Further, sodium acetate (23.53 mg, 0.34 mmol), N-cyanoacetylurethane (165.3 mg, 1.06 mmol), and the like were added. ) was added, the ice bath was removed, the mixture was allowed to warm to room temperature, and the reaction was continued for 12 hours. 15 mL of water was added, and a solid was formed. The solid was filtered and dried to give ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopentyl-6-oxo-1,6-dihydropyridine-3-oxy)phenyl)hydrazone)acetyl)carbamate 12b (189.0 mg, yellow solid) in a 24.0% yield. MS m / z (ESI): 506.10 [M+1] + . Third step 2-(3,5-dichloro-4-((1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile The crude (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-oxy)phenyl)hydrazone)acetyl)ethyl carbamate 12b (189.0 mg, 0.37 mmol) was dissolved in N,N-dimethylacetamide (5.0 mL), and potassium acetate (109.0 mg, 1.12 mmol) was added. The mixture was then reacted at 120°C for 3 hours. The solvent was removed, and the resulting mixture was purified by preparative HPLC to give 2-(3,5-dichloro-4-((1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 12 (120.0 mg, white solid) in 70.1% yield. MS m / z (ESI):460.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.29 (s,1H),7.79 (s,2H),7.44 (d,J = 3.2 Hz,1H),7.27 (dd,J = 10.0,3.2 Hz,1H),6.39 (d,J = 10.0 Hz,1H),5.04-4.98 (m,1H),2.00-1.90 (m,2H),1.81 - 1.53 (m,6H).

[0134] Example 13 2-(3,5-dichloro-4-((1-(cyclohex-1-en-1-yl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0135] [ka]

[0136] First step 1-(cyclohex-1-en-1-yl)-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 5-(2,6-Dichloro-4-nitrophenoxy)-2-hydroxypyridine 1c (2.00 g, 6.6 mmol) was dissolved in 40 mL of toluene. Cyclohexenylboronic acid (3.60 g, 26.6 mmol), copper acetate (1.20 g, 6.6 mmol), di(trimethylsilyl)aminosodium (1.20 g, 6.6 mmol), and pyridine (2.68 mL, 33.0 mmol) were added, and the mixture was then reacted at 80 °C for 4 hours. The solvent was removed by concentration under reduced pressure, and the mixture was purified by flash silica gel column chromatography to give 1-(cyclohex-1-en-1-yl)-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 13a (720.0 m, yellow solid) in 28.5% yield. MS m / z (ESI): 381.00 [M+1] + . Second step 5-(4-amino-2,6-dichlorophenoxy)-1-(cyclohex-1-en-1-yl)pyridin-2(1H)-one 1-(Cyclohex-1-en-1-yl)-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 13a (200.0 mg, 0.53 mmol) and reduced iron powder (147.0 mg) were dissolved in a mixture of 1 mL of ethanol and 1 mL of saturated ammonium chloride, refluxed for 2 hours, concentrated under reduced pressure to remove ethanol, extracted with dichloromethane (2 mL × 3), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash chromatography to give 5-(4-amino-2,6-dichlorophenoxy)-1-(cyclohex-1-en-1-yl)pyridin-2(1H)-one 13b (126.0 mg, yellow oil) in 68.4% yield. MS m / z (ESI): 351.00 [M+1] + . Third step Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-(cyclohex-1-en-1-yl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazine)acetyl)carbamate 5-(4-amino-2,6-dichlorophenoxy)-1-(cyclohex-1-en-1-yl)pyridin-2(1H)-one 13b The resulting mixture (126.0 mg, 0.36 mmol) was dissolved in a mixed solvent consisting of 3.2 mL of acetic acid, 0.8 mL of water, and 0.4 mL of concentrated hydrochloric acid. Sodium nitrite (31.0 mg, 0.44 mmol) was added at 0°C, and the mixture was allowed to react for 10 minutes. After that, sodium acetate (90.0 mg, 1.10 mmol) was added, and after another 10 minutes of reaction, N-cyanoacetylurethane (69.0 mg, 0.44 mmol) was added. The mixture was warmed to room temperature and allowed to react for 72 hours. 5 mL of water was added, the mixture was filtered, and the mixture was dried by heating to obtain ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-(cyclohex-1-en-1-yl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazine)acetyl)carbamate 13c (70.0 mg, yellow solid) in a yield of 37.0%. MS m / z (ESI): 518.09 [M+1] + . Fourth step 2-(3,5-dichloro-4-((1-(cyclohex-1-en-1-yl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-(cyclohex-1-en-1-yl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazine)acetyl)carbamate 13c (55.0 mg, 0.11 mmol) was dissolved in 2.0 mL of N,N-dimethylacetamide, and potassium acetate (21.0 mg, 0.22 mmol) was added, followed by heating at 120°C. The reaction was continued for 2 hours, and the solvent was removed by concentration under reduced pressure. Purification by preparative chromatography afforded 2-(3,5-dichloro-4-((1-(cyclohex-1-en-1-yl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 13 (15.0 mg, white solid) in a 30.0% yield. MS m / z (ESI): 472.05 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 7.77 (s,2H),7.43 (d,J = 4.0 Hz,1H),7.21 (dd,J = 8.0,4.0 Hz,1H),6.41 (d,J = 8.0 Hz,1H),5.72-5.62 (m,1H),2.24-2.18 (m,2H),2.15-2.08 (m,2H),1.72-1.64 (m,2H),1.60-1.52 (m,2H).

[0137] Example 14 2-(3,5-dichloro-4-((deuterated 1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0138] [ka]

[0139] First step Deuterated Cyclopentanol Cyclopentanone 14a (5.00 g, 59.44 mmol) was dissolved in 100 mL of methanol, sodium borodeuteride (6.20 g, 148.60 mmol) was added, and the mixture was allowed to react at room temperature for 2 hours. The reaction was quenched by adding 2.0 mL of 1N hydrochloric acid, and the mixture was concentrated under reduced pressure to remove the solvent. 100 mL of dichloromethane was added, and the organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give deuterated cyclopentanol 14b (4.86 g, colorless oil) in a yield of 93.9%. Second step Deuterated cyclopentyl 4-toluene-1-sulfonate Deuterated cyclopentanol 14b (4.86 g, 55.8 mmol) was dissolved in 100 mL of dichloromethane. Then, p-toluenesulfonyl chloride (10.64 g, 55.8 mmol), 4-dimethylaminopyridine (0.68 g, 5.58 mmol), and triethylamine (16.94 g, 167.4 mmol) were added and stirred at room temperature for 12 hours. The solvent was removed, and the mixture was purified by column chromatography to give deuterated cyclopentyl 4-toluene-1-sulfonate 14c (3.20 g, colorless oil) in 23.5% yield. MS m / z (ESI): 240.31 [M+1] + . Third step Deuterated 1-cyclopentyl-5-(2,6-dichloro-4-nitrophenoxy)-1,2-dihydropyridin-2-one 5-(2,6-Dichloro-4-nitrophenoxy)-2-hydroxypyridine 1c (1.50 g, 4.98 mmol) was dissolved in 30.0 mL of 1,4-dioxane, and deuterated cyclopentyl 4-toluene-1-sulfonate 14c (2.4 g, 9.96 mmol) and cesium carbonate (4.87 g, 14.94 mmol) were added. The mixture was reacted at 100 °C for 2 hours. The solvent was removed by concentration under reduced pressure, and the product was purified by flash chromatography to give deuterated 1-cyclopentyl-5-(2,6-dichloro-4-nitrophenoxy)-1,2-dihydropyridin-2-one 14d (1.0 g, yellow solid) in 52.4% yield. MS m / z (ESI): 370.21 [M+1] + . Fourth step Deuterated 1-cyclopentyl-5-(2,6-dichloro-4-aminophenoxy)-1,2-dihydropyridin-2-one Deuterated 1-cyclopentyl-5-(2,6-dichloro-4-nitrophenoxy)-1,2-dihydropyridin-2-one 14d (985.0 mg, 2.67 mmol) was dissolved in a mixed solvent of 10.0 mL of saturated ammonium chloride and 10.0 mL of ethanol, and reduced iron powder (750.0 mg, 13.4 mmol) was added. The mixture was reacted at 100 °C for 2 hours, concentrated under reduced pressure to remove ethanol, and extracted with dichloromethane (20.0 mL × 3). The organic phase was dried over anhydrous sodium sulfate, and the filtrate was filtered and concentrated. The crude product was isolated and purified by flash silica gel column chromatography to give deuterated 1-cyclopentyl-5-(2,6-dichloro-4-aminophenoxy)-1,2-dihydropyridin-2-one 14e (720.0 mg, pale yellow oil) in 73.0% yield. MS m / z (ESI): 340.07 [M+1] + . Fifth step Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((deuterated 1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazine)acetyl)carbamate Deuterated 1-cyclopentyl-5-(2,6-dichloro-4-aminophenoxy)-1,2-dihydropyridin-2-one 14e (360.0 mg, 0.98 mmol) was dissolved in a mixed solvent consisting of 4.8 mL of acetic acid, 1.2 mL of water, and 0.6 mL of concentrated hydrochloric acid. Sodium nitrite (81.1 mg, 1.18 mmol) was added at 0 °C. The mixture was allowed to react for 10 minutes, followed by sodium acetate (241.2 mg, 2.94 mmol). After another 10 minutes of reaction, N-cyanoacetylurethane (183.6 mg, 1.18 mmol) was added. The mixture was warmed to room temperature and reacted for 72 hours. 10.0 mL of water was added, the mixture was filtered, and dried by heating to give ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((deuterated 1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazine)acetyl)carbamate 14f (620.0 mg, yellow solid) in 92.0% yield. The crude product was used directly in the next step. MS m / z (ESI): 507.10 [M+1] + . Sixth step 2-(3,5-dichloro-4-((deuterated 1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((deuterated 1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazine)acetyl)carbamate 14f (570.0 mg, 0.90 mmol) was dissolved in 10.0 mL of N,N-dimethylacetamide, and potassium acetate (176.7 mg, 1.80 mmol) was added. The mixture was reacted at 120 °C for 2 hours, concentrated under reduced pressure to remove the solvent, and the crude product was purified by preparative HPLC to give 2-(3,5-dichloro-4-((deuterated 1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 14. (70.0 mg, white solid) was obtained in a yield of 17.0%. MS m / z (ESI): 461.06 [M+1]+ . 1 H NMR (400 MHz,DMSO-d6) δ 7.79 (s,2H),7.43 (d,J = 4.0 Hz,1H),7.24 (dd,J = 4.0,8.0 Hz,1H),6.40 (d,J = 8.0 Hz,1H),1.97-1.95 (m,2H),1.76-1.59 (m,6H).

[0140] Example 15

[0141] [ka]

[0142] First step 2-(3,5-dichloro-4-[(5-chloro-1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 2-(3,5-Dichloro-4-((1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 12 (30.0 mg, 0.06 mmol) was dissolved in 3.0 mL of N,N-dimethylformamide, and N-chlorosuccinimide (12.0 mg, 0.09 mmol) was added. The mixture was heated to 70 °C and reacted for 1 hour. The solvent was removed, and the residue was purified by preparative HPLC to give 2-(3,5-dichloro-4-[(5-chloro-1-cyclopentyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 15. (13.0 mg, white solid) was obtained in a yield of 43.1%. MS m / z (ESI): 493.95 [M+1] + . 1H NMR (400 MHz,DMSO-d6) δ 13.30 (s,1H),7.82-7.76 (m,3H),7.52 (d,J = 2.8 Hz,1H),5.09-5.00 (m,1H),2.00-1.94 (m,2H),1.80-1.68 (m,4H),1.64-1.57 (m,2H).

[0143] Example 16 2-(3,5-dichloro-4-((1-cyclopentyl-5-fluoro-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0144] [ka]

[0145] First step 5-Fluoro-6-methoxypyridin-3-ol 5-Bromo-3-fluoro-2-methoxypyridine 16a (2.00 g, 9.71 mmol) and trimethyl borate (2.20 g, 21.17 mmol) were dissolved in 60.0 mL of anhydrous tetrahydrofuran, and the mixture was purged with nitrogen gas three times. At -78 ° C, n-butyllithium (8.74 mL, 2.5 N, 21.86 mmol) was added dropwise. After reacting at -78 ° C for 2 hours, 20% peracetic acid (8.10 g, 21.30 mmol) was added and the mixture was reacted for 10 minutes. The mixture was then heated to 0 ° C. and stirred for 1 hour. At 0 ° C., saturated sodium sulfite solution was added dropwise until the temperature did not rise again. 50 mL of ethyl acetate was added, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash chromatography to give 5-fluoro-6-methoxypyridin-3-ol 16b (755.0 mg, colorless oil) in a yield of 46.5%. MS m / z (ESI): 144.11 [M+1] + . Second step 5-(2,6-dichloro-4-nitrophenoxy)-3-fluoro-2-methoxypyridine 5-Fluoro-6-methoxypyridin-3-ol 16b (755.0 mg, 4.52 mmol) was dissolved in 10.0 mL of N,N-dimethylformamide, and 1,3-dichloro-2-fluoro-5-nitrobenzene (949.2 mg, 4.52 mmol) and potassium carbonate (1874.1 mg, 13.56 mmol) were added. The mixture was allowed to react at room temperature for 3 hours, followed by the addition of 80 mL of water. The mixture was filtered, concentrated under reduced pressure, and evaporated on a rotary evaporator to give 5-(2,6-dichloro-4-nitrophenoxy)-3-fluoro-2-methoxypyridine 16c (1.48 g, yellow solid) in 94.96% yield. MS m / z (ESI): 334.10 [M+1] + . Third step 5-(2,6-dichloro-4-nitrophenoxy)-3-fluoropyridin-2-ol 5-(2,6-Dichloro-4-nitrophenoxy)-3-fluoro-2-methoxypyridine 16c (1.43 g, 4.15 mmol) was dissolved in a mixed solvent of 15.0 mL of acetic acid and 15.0 mL of hydrobromic acid, and the mixture was reacted at 100 °C for 2 hours. The mixture was concentrated under reduced pressure to remove the solvent, cooled to room temperature, filtered, and dried under reduced pressure to give 5-(2,6-dichloro-4-nitrophenoxy)-3-fluoropyridin-2-ol 16d (1.30 g, yellow solid) in 97.0% yield. MS m / z (ESI): 320.07 [M+1] + . Fourth step 1-Cyclopentyl-5-(2,6-dichloro-4-nitrophenoxy)-3-fluoro-1,2-dihydropyridin-2-one 5-(2,6-Dichloro-4-nitrophenoxy)-3-fluoropyridin-2-ol 16d (1.25 g, 3.85 mmol) was dissolved in 25.0 mL of 1,4-dioxane, and cyclopentyl 4-toluene-1-sulfonate (2.78 g, 11.55 mmol) and cesium carbonate (3.76 g, 11.55 mmol) were added. The mixture was reacted at 100 °C for 2 hours, concentrated under reduced pressure to remove the solvent, and purified by flash chromatography to give 1-cyclopentyl-5-(2,6-dichloro-4-nitrophenoxy)-3-fluoro-1,2-dihydropyridin-2-one 16e (520.0 mg, yellow solid) in a 34.3% yield. MS m / z (ESI): 388.19 [M+1] + . Fifth step 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopentyl-3-fluoro-1,2-dihydropyridin-2-one 1-Cyclopentyl-5-(2,6-dichloro-4-nitrophenoxy)-3-fluoro-1,2-dihydropyridin-2-one 16e (470.0 mg, 1.19 mmol) was dissolved in a mixed solvent of saturated ammonium chloride (10.0 mL) and ethanol (10.0 mL). Reduced iron powder (332.3 mg, 5.95 mmol) was added and the mixture was reacted at 100 °C for 2 hours. The mixture was concentrated under reduced pressure to remove ethanol, and extracted with dichloromethane (20.0 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by flash silica gel column chromatography to give 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopentyl-3-fluoro-1,2-dihydropyridin-2-one 16f (288.0 mg, pale yellow oil) in 53.3% yield. MS m / z (ESI): 357.21 [M+1] + . Sixth step N-[(E)-Cyanoethyl(2-(3,5-dichloro-4-[(1-cyclopentyl-5-fluoro-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)hydrazin-1-ylidene)carbonyl]carbamate 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopentyl-3-fluoro-1,2-dihydropyridin-2-one 16f (144.0 mg, 0.32 mmol) was dissolved in a mixed solvent consisting of 3.2 mL of acetic acid, 0.8 mL of water, and 0.4 mL of concentrated hydrochloric acid, and sodium nitrite (26.5 mg, 0.38 mmol) was added at 0 ° C. and reacted for 10 minutes, after which sodium acetate (78.8 mg, 0.96 mmol) was added, and after another 10 minutes of reaction, N-cyanoacetylurethane (59.9 mg, 0.38 mmol) was added, and the temperature was raised to room temperature and reacted for 72 hours, and 5.0 mL of water was added, filtered, and dried by heating to obtain 16 g of N-[(E)-cyanoethyl (2-(3,5-dichloro-4-[(1-cyclopentyl-5-fluoro-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)hydrazin-1-ylidene)carbonyl]carbamate (183.0 mg, yellow solid) in a yield of 79.0%. MS m / z (ESI): 524.33 [M+1] + . Seventh step 2-(3,5-dichloro-4-[(1-cyclopentyl-5-fluoro-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (N-[(E)-cyanoethyl(2-(3,5-dichloro-4-[(1-cyclopentyl-5-fluoro-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)hydrazin-1-ylidene)carbonyl]carbamate 16g (183.0 mg, 0.25 mmol) was dissolved in 3.0 mL of N,N-dimethylacetamide, potassium acetate (73.61 mg, 0.75 mmol) was added, and the mixture was reacted at 120°C for 2 hours. The mixture was concentrated under reduced pressure to remove the solvent, and the resulting mixture was purified by preparative chromatography to obtain 2-(3,5-dichloro-4-[(1-cyclopentyl-5-fluoro-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 16 (70.0 mg, white solid) was obtained in a yield of 31.2%. MS m / z (ESI): 478.26 [M+1]+ . 1 H NMR (400 MHz,DMSO-d6) δ 7.78 (s,2H),7.56 (d,J = 4.0 Hz,1H),7.30 (d,J = 4.0 Hz,1H),5.08-5.04 (m,2H),1.97-1.95 (m,2H),1.74-1.60 (m,6H).

[0146] Example 17 2-(3,5-dichloro-4-[(1-cyclopentyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0147] [ka]

[0148] First step Cyclopentyl 4-toluene-1-sulfonate Cyclopentanol 17a (10.00 g, 116.10 mmol) was dissolved in 100 mL of dichloromethane, followed by the addition of p-toluenesulfonyl chloride (22.13 g, 116.10 mmol), 4-dimethylaminopyridine (1.42 g, 11.61 mmol), and triethylamine (29.37 g, 290.25 mmol) and stirring at room temperature for 12 h. The solvent was removed, and the resulting mixture was subjected to flash silica gel column chromatography to give cyclopentyl 4-toluene-1-sulfonate 17b (13.12 g, colorless oil) in 42.8% yield. Second step 5-Bromo-1-cyclopentyl-3-methyl-1,2-dihydropyridin-2-one Cyclopentyl 4-toluene-1-sulfonate 17b (3.77 g, 15.96 mmol) was dissolved in 10 mL of 1,2-dimethoxyethane, followed by the addition of 5-bromo-3-methylpyridin-2-one (1.00 g, 5.32 mmol) and potassium carbonate (2.21 g, 15.96 mmol). The mixture was heated to 80 °C and reacted for 12 hours. The solvent was removed, and the resulting mixture was purified by flash silica gel column chromatography to give 5-bromo-1-cyclopentyl-3-methyl-1,2-dihydropyridin-2-one 17c (0.92 g, white solid) in 62.1% yield. MS m / z (ESI): 256.05 [M+1] + . 1 H NMR (400 MHz,CDCl3) δ 7.31 (d,J = 2.4 Hz,1H),7.22 (d,J = 1.2 Hz,1H),5.32-5.24 (m,1H),2.23 - 2.11 (m,5H),1.88-1.84 (m,2H),1.78 - 1.71 (m,2H),1.65-1.60 (m,2H). Third step 1-Cyclopentyl-3-methyl-5-(tetramethyl-1,3,2-dioxin-2-yl)-1,2-dihydropyridin-2-one 5-Bromo-1-cyclopentyl-3-methyl-1,2-dihydropyridin-2-one 17c (300.0 mg, 1.08 mmol), diboronic acid pinacol ester (411.3 mg, 1.62 mmol), potassium acetate (317.9 mg, 3.24 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (79.0 mg, 0.11 mmol) were dissolved in 1,4-dioxane (10 mL), purged with nitrogen gas, heated to 100 ° C, reacted for 6 hours, removed the solvent, and purified by flash silica gel column chromatography to give 1-cyclopentyl-3-methyl-5-(tetramethyl-1,3,2-dioxin-2-yl)-1,2-dihydropyridin-2-one 17d (343.0 mg, colorless oil) in 71.2% yield. MS m / z (ESI): 304.15 [M+1] + . Fourth step 1-Cyclopentyl-5-hydroxy-3-methyl-1,2-dihydropyridin-2-one 1-Cyclopentyl-3-methyl-5-(tetramethyl-1,3,2-dioxin-2-yl)-1,2-dihydropyridin-2-one 17d (100.0 mg, 0.22 mmol) was dissolved in 5.0 mL of N,N-dimethylformamide, the temperature was lowered to 0 °C, and peracetic acid (167.3 mg, 0.44 mmol) was added dropwise. The mixture was then allowed to react at 0 °C for 1 hour. 1.0 mL of saturated aqueous sodium sulfite solution was added, and the resulting 1-cyclopentyl-5-hydroxy-3-methyl-1,2-dihydropyridin-2-one 17e was used directly in the next step without further purification. MS m / z (ESI): 194.15 [M+1] + . Fifth step 1-Cyclopentyl-5-(2,6-dichloro-4-nitrophenoxy)-3-methyl-1,2-dihydropyridin-2-one 1,3-Dichloro-2-fluoro-5-nitrobenzene (46.2 mg, 0.22 mmol) and potassium carbonate (304.0 mg, 2.20 mmol) were dissolved in the 1-cyclopentyl-5-hydroxy-3-methyl-1,2-dihydropyridin-2-one 17e reaction mixture, and the mixture was allowed to react at room temperature for 3 hours. The solvent was removed and the residue was purified by flash silica gel column chromatography to give 1-cyclopentyl-5-(2,6-dichloro-4-nitrophenoxy)-3-methyl-1,2-dihydropyridin-2-one 17f (0.07 g, yellow oil) in 59.8% yield. MS m / z (ESI): 383.00 [M+1] + . Sixth step 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopentyl-3-methyl-1,2-dihydropyridin-2-one 1-Cyclopentyl-5-(2,6-dichloro-4-nitrophenoxy)-3-methyl-1,2-dihydropyridin-2-one 17f (70.0 mg, 0.13 mmol) was dissolved in 5.0 mL of ethanol, followed by the addition of tin(II) chloride dihydrate (117.3 mg, 0.52 mmol). The mixture was heated to 80 °C and reacted for 2 hours. The pH was adjusted to greater than 7 with aqueous sodium hydroxide, the solvent was removed, and the residue was purified by flash silica gel column chromatography to give 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopentyl-3-methyl-1,2-dihydropyridin-2-one 17g (70.0 mg, white solid) in 98.0% yield. MS m / z (ESI): 353.10 [M+1] + . Seventh step Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopentyl-5-methyl-6-oxo-1,6-dihydropyridin-3-l)oxy)phenyl)hydrazine)acetyl)carbamate 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopentyl-3-methyl-1,2-dihydropyridin-2-one 17g (70.0 mg, 0.18 mmol) was dissolved in 3 mL of acetic acid and 1 mL of water, the temperature was lowered to 0°C, 0.5 mL of concentrated hydrochloric acid was added, 1 mL of aqueous sodium nitrite (13.6 mg, 0.20 mmol) was slowly added dropwise, and the mixture was stirred for 10 minutes. Sodium acetate (44.3 mg, 0.54 mmol) and N-cyanoacetylurethane (28.1 mg, 0.18 mmol) were added, the ice bath was removed, the mixture was warmed to room temperature, and the mixture was allowed to react for 12 hours. 10 mL of water was added, and the solid was filtered and dried to give ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopentyl-5-methyl-6-oxo-1,6-dihydropyridine-3-l)oxy)phenyl)hydrazine)acetyl)carbamate 17h (100.0 mg, yellow solid) in a yield of 51.0%. The crude product was used directly in the next step. MS m / z (ESI): 520.00 [M+1] + . Eighth step 2-(3,5-dichloro-4-[(1-cyclopentyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile The crude product of ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopentyl-5-methyl-6-oxo-1,6-dihydropyridine-3-l)oxy)phenyl)hydrazine)acetyl)carbamate 17h (100.0 mg, 0.09 mmol) was dissolved in N,N-dimethylacetamide (5.0 mL), potassium acetate (26.5 mg, 0.27 mmol) was added, and the mixture was reacted at 120°C for 3 hours. The solvent was removed, and the resulting product was purified by preparative HPLC to give 2-(3,5-dichloro-4-[(1-cyclopentyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 17 (8.0 mg, white solid) in a 17.6% yield. MS m / z (ESI): 474.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.30 (s,1H),7.78 (s,2H),7.22 (s,2H),5.05-5.15 (m,1H),2.01 (s,3H),1.98-1.94 (m,2H),1.78-1.70 (s,2H),1.68-1.60 (m,2H).

[0149] Example 18 2-(3,5-dichloro-4-((1-cyclopropyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0150] [ka]

[0151] First step 5-Bromo-1-cyclopropyl-3-methylpyridin-2(1H)-one 5-Bromo-3-methylpyridin-2-one 18a (2.00 g, 10.6 mmol) was dissolved in 20 mL of 1,2-dichloroethane. 2,2'-Bipyridine (8.31 g, 53.2 mmol), copper acetate (1.58 g, 12.7 mmol), cyclopropylboronic acid (1.37 g, 15.9 mmol), and sodium carbonate (2.26 g, 21.2 mmol) were added and the mixture was reacted at 70 °C for 6 hours. The solvent was removed and the residue was purified by flash silica gel column chromatography to give 5-bromo-1-cyclopropyl-3-methyl-1,2-dihydropyridin-2-one 18b (2.10 g, white solid) in 84.9% yield. MS m / z (ESI): 228.05 [M+1] + . Second step 1-Cyclopropyl-3-methyl-5-(tetramethyl-1,3,2-dioxin-2-yl)-1,2-dihydropyridin-2-one 5-Bromo-1-cyclopropyl-3-methyl-1,2-dihydropyridin-2-one 18b (1.50 g, 6.5 mmol), 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxal-2-yl)-1,3,2-dioxanol (1.64 g, 6.5 mmol), potassium acetate (0.63 g, 6.5 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) (4.73 g, 6.5 mmol) was dissolved in 20 mL of 1,4-dioxane, purged with nitrogen gas, heated to 100 °C, and reacted for 6 hours. The solvent was removed and purified by flash silica gel column chromatography to give 1-cyclopropyl-3-methyl-5-(tetramethyl-1,3,2-dioxin-2-yl)-1,2-dihydropyridin-2-one 18c (1.78 g, colorless oil) in 82.4% yield. MS m / z (ESI): 276.15 [M+1] + . Third step 1-Cyclopropyl-5-hydroxy-3-methyl-1,2-dihydropyridin-2-one 1-Cyclopropyl-3-methyl-5-(tetramethyl-1,3,2-dioxin-2-yl)-1,2-dihydropyridin-2-one 18c (0.30 g, 0.90 mmol) was dissolved in 5.0 mL of N,N-dimethylformamide, the temperature was lowered to 0 °C, hydrogen peroxide (0.09 g, 0.79 mmol) was added dropwise, and the mixture was then warmed to room temperature and reacted for 12 hours. The resulting 1-cyclopropyl-5-hydroxy-3-methyl-1,2-dihydropyridin-2-one 18d was used directly in the next step without further purification. MS m / z (ESI): 166.20 [M+1] + . Fourth step 1-Cyclopropyl-5-(2,6-dichloro-4-nitrophenoxy)-3-methyl-1,2-dihydropyridin-2-one 1,3-Dichloro-2-fluoro-5-nitrobenzene (0.20 g, 0.98 mmol) and potassium carbonate (0.27 g, 1.95 mmol) were dissolved in the 1-cyclopropyl-5-hydroxy-3-methyl-1,2-dihydropyridin-2-one 18d reaction mixture, and the mixture was allowed to react at room temperature for 3 hours. The solvent was removed and the residue was purified by flash silica gel column chromatography to give 1-cyclopropyl-5-(2,6-dichloro-4-nitrophenoxy)-3-methyl-1,2-dihydropyridin-2-one 18e (0.24 g, colorless oil) in 88.0% yield. MS m / z (ESI): 355.00 [M+1] + . Fifth step 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopropyl-3-methyl-1,2-dihydropyridin-2-one 1-Cyclopropyl-5-(2,6-dichloro-4-nitrophenoxy)-3-methyl-1,2-dihydropyridin-2-one 18e (0.24 g, 0.57 mmol) and tin(II) chloride dihydrate (0.64 g, 2.85 mmol) were dissolved in 5.0 mL of ethanol, heated to 80 °C, and reacted for 3 h. The pH was adjusted to greater than 7 with aqueous sodium hydroxide, the solvent was removed, and the residue was purified by flash silica gel column chromatography to give 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopropyl-3-methyl-1,2-dihydropyridin-2-one 18f (0.13 g, yellow solid) in 69.9% yield. MS m / z (ESI): 325.05 [M+1] + . Sixth step Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopropyl-5-methyl-6-oxo-1,6-dihydropyridine-3-l)oxy)phenyl)hydrazone)acetyl)carbamate 5-(4-amino-2,6-dichlorophenoxy)-1-cyclopropyl-3-methyl-1,2-dihydropyridin-2-one 18f (0.13 g, 0.40 mmol) was dissolved in 4 mL of acetic acid and 1.0 mL of water, the temperature was lowered to 0°C, 0.5 mL of concentrated hydrochloric acid was added, 1 mL of aqueous sodium nitrite (0.03 g, 0.48 mmol) was slowly added dropwise, and the mixture was stirred for 10 minutes. Anoacetylurethane (0.06 g, 0.40 mmol) was added, the ice bath was removed, the mixture was allowed to warm to room temperature, and the mixture was allowed to react for 12 hours. 10 mL of water was added, and the solid was filtered and dried to give ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopropyl-5-methyl-6-oxo-1,6-dihydropyridine-3-l)oxy)phenyl)hydrazone)acetyl)carbamate 18g (0.06 g, yellow solid) in a yield of 22.6%. The crude product was used directly in the next step. MS m / z (ESI): 492.00 [M+1] + . Seventh step 2-(3,5-dichloro-4-[(1-cyclopropyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 18 g (0.06 g, 0.09 mmol) of crude ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopropyl-5-methyl-6-oxo-1,6-dihydropyridine-3-l)oxy)phenyl)hydrazone)acetyl)carbamate was dissolved in N,N-dimethylacetamide (5.0 mL), and potassium acetate (0.01 g, 0.12 mmol) was added. The mixture was then reacted at 120°C for 3 hours. The solvent was removed, and the resulting product was purified by preparative HPLC to give 2-(3,5-dichloro-4-[(1-cyclopropyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 18 (30.0 mg, white solid) in 74.3% yield. MS m / z (ESI): 446.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.28 (s,1H),7.78 (s,2H),7.24 (d,J = 2.0 Hz,1H),7.09 (d,J = 3.2 Hz,1H),3.34 - 3.28 (m,1H),2.01 (s,3H),0.99-0.94 (m,2H),0.80-0.75 (m,2H).

[0152] Example 19 2-(3,5-dichloro-4-((5-cyclopropyl-1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0153] [ka]

[0154] First step 3-Cyclopropyl-5-(2,6-dichloro-4-nitrophenoxy)-1-ethyl-1,2-dihydropyridin-2-one 5-(2,6-Dichloro-4-nitrophenoxy)-3-iodo-1-(propan-2-yl)-1,2-dihydropyridin-2-one 19a (200.0 mg, 0.39 mmol) was dissolved in 5.0 mL of 1,4-dioxane, followed by the addition of cyclopropyl borate (100.5 mg, 1.17 mmol), potassium phosphate tripotassium (248.3 mg, 1.17 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (28.5 mg, 0.04 mmol). The mixture was heated to 100 °C under nitrogen gas protection for 8 hours. The solvent was removed, and the resulting mixture was purified by flash silica gel column chromatography to give 3-cyclopropyl-5-(2,6-dichloro-4-nitrophenoxy)-1-ethyl-1,2-dihydropyridin-2-one 19b. (150.0 mg, yellow solid) was obtained in a yield of 93.7%. MS m / z (ESI): 383.00 [M+1] + . Second step 5-(4-amino-2,6-dichlorophenoxy)-3-cyclopropyl-1-(propan-2-yl)-1,2-dihydropyridin-2-one 3-Cyclopropyl-5-(2,6-dichloro-4-nitrophenoxy)-1-ethyl-1,2-dihydropyridin-2-one 19b (150.0 mg, 0.35 mmol) and tin(II) chloride dihydrate (394.8 mg, 1.75 mmol) were dissolved in 10.0 mL of ethanol, heated to 80 °C, and reacted for 3 h. The pH was adjusted to greater than 7 with aqueous sodium hydroxide, the solvent was removed, and the mixture was purified by flash silica gel column chromatography to give 5-(4-amino-2,6-dichlorophenoxy)-3-cyclopropyl-1-(propan-2-yl)-1,2-dihydropyridin-2-one 19c (122.0 mg, yellow solid) in 89.8% yield. MS m / z (ESI): 353.10 [M+1] + . Third step Ethyl N-[(Z)-cyano(2-(3,5-dichloro-4-[(5-cyclopropyl-6-oxo-1-(propan-2-yl)-1,6-dihydropyridin-3-yl)oxy]phenyl)hydrazin-1-ylidene)carbonyl]carbamate 5-(4-amino-2,6-dichlorophenoxy)-3-cyclopropyl-1-(propan-2-yl)-1,2-dihydropyridin-2-one 19c (122.0 mg, 0.31 mmol) was dissolved in 4.0 mL of acetic acid and 1.0 mL of water, the temperature was lowered to zero, 0.5 mL of concentrated hydrochloric acid was added, 4.0 mL of aqueous sodium nitrite (0.03 g, 0.48 mmol) was slowly added dropwise, and the mixture was stirred for 10 minutes. Sodium acetate (23.5 mg, 0.34 mmol) and N-cyanoacetylurethane (96.8 mg, 0.62 mmol) were added, the ice bath was removed, the mixture was warmed to room temperature, and the mixture was reacted for 12 hours. 10 mL of water was added, and the solid was filtered and dried. Ethyl N-[(Z)-cyano(2-(3,5-dichloro-4-[(5-cyclopropyl-6-oxo-1-(propan-2-yl)-1,6-dihydropyridin-3-yl)oxy]phenyl)hydrazin-1-ylidene)carbonyl]carbamate 19d (300.0 mg, yellow solid). The crude product was used directly in the next step. MS m / z (ESI): 520.05 [M+1] + . Fourth step 2-(3,5-dichloro-4-[(5-cyclopropyl-6-oxo-1-(propan-2-yl)-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile The crude product of ethyl N-[(Z)-cyano(2-(3,5-dichloro-4-[(5-cyclopropyl-6-oxo-1-(propan-2-yl)-1,6-dihydropyridin-3-yl)oxy]phenyl)hydrazin-1-ylidene)carbonyl]carbamate 19d (140.0 mg, 0.25 mmol) was dissolved in N,N-dimethylacetamide (5.0 mL), potassium acetate (73.6 mg, 0.75 mmol) was added, and the mixture was reacted at 120°C for 3 hours. The solvent was removed, and the resulting product was purified by preparative HPLC to give 2-(3,5-dichloro-4-[(5-cyclopropyl-6-oxo-1-(propan-2-yl)-1,6-dihydropyridin-3-yl)oxy]phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 19 (19.0 mg, white solid) in a 15.8% yield. MS m / z (ESI): 474.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.36 (s,1H),7.85 (s,2H),7.21 (d,J = 3.2 Hz,1H),6.93 (d,J = 2.8 Hz,1H),5.18-5.11 (m,1H),2.18 - 2.10 (m,1H),1.31 (d,J = 6.8 Hz,6H),0.97-0.92 (m,2H),0.77-0.73 (m,2H).

[0155] Example 20 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0156] [ka]

[0157] First step 5-(2,6-dichloro-4-nitrophenoxy)-1-phenylpyridin-2(1H)-one 5-(4-nitro-2,6-dichlorophenoxy)-2-carbonylpyridine 1c (2.00 g, 6.22 mmol) was dissolved in 200 mL of anhydrous dichloromethane, and then phenylboronic acid (2.28 g, 18.66 mmol), triethylamine (3.46 mL, 34.88 mmol), and copper acetate (0.77 g, 6.22 mmol) were added in that order. The mixture was then reacted at 20 °C for 16 hours. Water was added to the reaction mixture, which was then extracted three times with ethyl acetate, dried over anhydrous sodium sulfate, filtered, and purified by flash column chromatography (PE:EA = 1:2) to give 5-(2,6-dichloro-4-nitrophenoxy)-1-phenylpyridin-2(1H)-one 20a (2.30 g, yellow solid) in 83.6% yield. MS m / z (ESI): 377.00 [M+1] + . Second step 5-(2,6-dichloro-4-aminophenoxy)-1-phenylpyridin-2(1H)-one 5-(2,6-Dichloro-4-nitrophenoxy)-1-phenylpyridin-2(1H)-one 20a (2.30 g, 5.20 mmol) was dissolved in 30 mL of methanol, and then iron powder (1.16 g, 20.80 mmol) and ammonium chloride (0.56 g, 10.40 mmol) dissolved in 1.5 mL of aqueous solution were added. The mixture was then reacted at 85 °C for 4 hours. The reaction mixture was concentrated, and then extracted three times with 20 mL of water and 35 mL of ethyl acetate. The mixture was dried over anhydrous sodium sulfate, filtered, and the organic phase was evaporated on a rotary evaporator to give 5-(2,6-dichloro-4-aminophenoxy)-1-phenylpyridin-2(1H)-one 20b (2.10 g, brown solid) in 95.7% yield. MS m / z (ESI): 347.00 [M+1] + . Third step (E)-(2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetylcarbamic acid ethyl ester Compound 5-(2,6-dichloro-4-aminophenoxy)-1-phenylpyridin-2(1H)-one 20b (2.00 g, 4.74 mmol) was dissolved in 30 mL of 6N hydrochloric acid solution, the temperature was lowered to 0 °C, and then sodium nitrite (0.49 g, 7.11 mmol) dissolved in 1 mL of aqueous solution was slowly added dropwise, and the reaction solution was stirred for 15 minutes. Next, N-cyanoacetylurethane (1.11 g, 7.11 mmol) was dissolved in 20 mL of water, the temperature was lowered to 0 °C, and then 32 mL of pyridine was added thereto and stirred at 0 °C for 10 minutes. The latter reaction solution was then slowly added dropwise to the former reaction solution and reacted at 0 °C for 30 minutes. 20 mL of water was added to the reaction mixture, and a large amount of solid precipitated. The mixture was then filtered, and the filter cake was dissolved in absolute ethanol and concentrated. This process was repeated 2 to 3 times. The crude product of (E)-(2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetylcarbamate 20c (2.65 g, red solid) was used directly in the next step. MS m / z (ESI): 514.05 [M+1] + . Fourth step 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile Ethyl ((E)-(2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetylcarbamate 20c (2.65 g, 4.59 mmol) was dissolved in 30 mL of N,N-dimethylacetamide, and then sodium acetate (1.13 g, 13.77 mmol) was added. The mixture was heated to 120°C and reacted at that temperature for 4 hours. 20 mL of water was added to the reaction solution, and ethyl acetate (30 mL × The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by flash column chromatography to obtain the crude product. 450 mg of the crude product was separated by prep-HPLC to obtain 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 20 (290.0 mg, white solid) in a 66.4% yield. MS m / z (ESI): 467.95 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 7.76 (s,2H),7.58 - 7.47 (m,3H),7.46 - 7.41 (m,2H),7.37-7.33 (m,2H),6.55 (d,J = 10.0 Hz,1H).

[0158] Example 21 2-(3,5-dichloro-4-((1-(4-fluorophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0159] [ka]

[0160] Using the method of Example 20, substituting p-fluorobenzeneboronic acid for phenylboronic acid, the title product, 2-(3,5-dichloro-4-((1-(4-fluorophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 21 (273.0 mg, white solid) was prepared in 64.8% yield. MS m / z (ESI): 485.95 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.26 (s,1H),7.75 (s,2H),7.53 (dd,J = 10.0 Hz,3.2 Hz,1H),7.47 (d,J = 2.8 Hz,1H),7.44 - 7.38 (m,2H),7.36 - 7.27 (m,2H),6.54 (d,J = 10.0 Hz,1H).

[0161] Example 22 2-(3,5-dichloro-4-((1-(3-fluorophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0162] [ka]

[0163] Using the method of Example 20, substituting m-fluorophenylboronic acid for phenylboronic acid, the title product 2-(3,5-dichloro-4-((1-(3-fluorophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 22 (30 mg, pale yellow solid, 34.18% yield) was prepared. MS m / z (ESI): 485.95 [M+1] + . 1H NMR (400 MHz,DMSO-d6) δ 7.75 (s,2H),7.62-7.58 (m,1H),7.47 (d,J = 2.8 Hz,3H),7.35 - 7.20 (m,3H),6.55 (d,J = 8.0 Hz,1H).

[0164] Example 23 2-(3,5-dichloro-4-((6-oxo-1-(3-(trifluoromethyl)phenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0165] [ka]

[0166] Using the method of Example 20, substituting m-trifluoromethylphenylboronic acid for phenylboronic acid, the title product, 2-(3,5-dichloro-4-((6-oxo-1-(3-(trifluoromethyl)phenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 23 (17.0 mg, white solid, 99.8% yield). MS m / z (ESI): 536.01 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.25(s,1H),7.81 (s,2H),7.78-7.72 (m,3H),7.70-7.65(m,1H),7.62 (d,J = 4.0 Hz,1H),7.55(dd,J = 4.0,4.0 Hz ,1H),6.57 (d,J = 12.0 Hz,1H).

[0167] Example 24 2-(3,5-dichloro-4-((6-oxo-1-(3-(trifluoromethoxy)phenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0168] [ka]

[0169] Using the method of Example 20, substituting m-trifluoromethoxyphenylboronic acid for phenylboronic acid, the title product 2-(3,5-dichloro-4-((6-oxo-1-(3-(trifluoromethoxy)phenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 24 (40.0 mg, white solid, 90.1% yield). MS m / z (ESI): 551.95 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.26(s,1H),7.76 (s,2H),7.63 (t,J = 8.0 Hz,1H),7.56-7.40 (m,5H),6.56 (d,J = 8.0 Hz,1H).

[0170] Example 25 2-(3,5-dichloro-4-((6-oxo-1-(4-methylphenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0171] [ka]

[0172] Using the method of Example 20, substituting p-tolueneboronic acid for phenylboronic acid, the title product, 2-(3,5-dichloro-4-((6-oxo-1-(4-methylphenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 25 (50.0 mg, pale yellow solid, 38.02% yield) was prepared. MS m / z (ESI): 482.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.25(s,1H),7.75 (s,2H),7.50 (dd,J = 10.0,3.2 Hz,1H),7.36 (d,J = 3.2 Hz,1H),7.30-7.19 (m,4H),6.52 (d,J = 10.0 Hz,1H),2.33 (s,3H).

[0173] Example 26 2-(3,5-dichloro-4-((6-oxo-1-(3-methylphenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0174] [ka]

[0175] Using the method of Example 20, substituting m-tolueneboronic acid for phenylboronic acid, the title product, 2-(3,5-dichloro-4-((6-oxo-1-(3-methylphenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 26 (280.00 mg, white solid, 22.86% yield). MS m / z (ESI): 482.28 [M+1] + . 1H NMR (400 MHz,DMSO-d6) δ 7.76 (s,2H),7.51 (dd,J = 10.0,3.2Hz,1H),7.40 (d,J = 3.2 Hz,1H),7.36 (d,J = 8.0 Hz,1H),7.24 (d,J = 8.0 Hz,1H),7.18 (s,1H),7.13 (d,J = 8.0 Hz,1H),6.53 (d,J = 10.0 Hz,1H),2.34 (s,3H).

[0176] Example 27 2-(3,5-dichloro-4-((6-oxo-1-(o-tolyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-1,2,3,4-4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0177] [ka]

[0178] Using the method of Example 20, substituting o-tolylboronic acid for phenylboronic acid, the title product 2-(3,5-dichloro-4-((6-oxo-1-(o-tolyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-1,2,3,4-4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 27 (61.1 mg, white solid, 40.45% yield). MS m / z (ESI): 482.28 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.25(s,1H),7.74 (s,2H),7.58 (dd,J = 10.0,4.0 Hz,1H),7.35 (d,J = 4.0 Hz,2H),7.33 - 7.26 (m,2H),7.19 (d,J = 8.0 Hz,1H),6.56 (d,J = 10.0 Hz,1H),2.03 (s,3H).

[0179] Example 28 2-(3,5-dichloro-4-((1-(3-cyanophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-1,2,3,4- 4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0180] [ka]

[0181] Using the method of Example 20, substituting m-cyanophenylboronic acid for phenylboronic acid, the title product, 2-(3,5-dichloro-4-((1-(3-cyanophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-1,2,3,4-4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 28 (125.1 mg, white solid, 78.61% yield). MS m / z (ESI): 493.26 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.25(s,1H),7.96 (s,1H),7.91 (d,J = 7.2 Hz,1H),7.76 (s,2H),7.74 - 7.66 (m,2H),7.62 - 7.51 (m,2H),6.58 (d,J = 10.0Hz,1H).

[0182] Example 29 2-(3,5-dichloro-4-((1-(3,5-difluorophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0183] [ka]

[0184] Using the method of Example 20, substituting 3,5-difluorophenylboronic acid for phenylboronic acid, the title product, 2-(3,5-dichloro-4-((1-(3,5-difluorophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 29 (50.0 mg, white solid, 98.84% yield). MS m / z (ESI): 504.23 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.24(s,1H),7.76(s,2H),7.58-7.50 (m,2H),7.41-7.33 (m,1H),7.30-7.23 (m,2H),6.60-6.51 (m,1H).

[0185] Example 30 2-(3,5-dichloro-4-((1-(3,5-dimethylphenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0186] [ka]

[0187] Using the method of Example 20, substituting 3,5-dimethylphenylboronic acid for phenylboronic acid, the title product, 2-(3,5-dichloro-4-((1-(3,5-dimethylphenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2-,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 30 (262.1 mg, white solid, 24.68% yield). MS m / z (ESI): 496.3 [M+1] + . 1H NMR (400 MHz,DMSO-d6) δ13.25(s,1H),7.76 (s,2H),7.49 (dd,J = 10.0,4.0 Hz,1H),7.36 (d,J = 4.0 Hz,1H),7.06 (s,1H),6.95 (s,2H),6.51 (d,J = 10.0 Hz, 1H), 2.30 (s, 6H). Example 31 2-(3,5-dichloro-4-((1-(3-cyclopropylphenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0188] [ka]

[0189] Using the method of Example 20, substituting 3-cyclopropylphenylboronic acid for phenylboronic acid, the title product, 2-(3,5-dichloro-4-((1-(3-cyclopropylphenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 31 (50.0 mg, white solid, 97.47% yield). MS m / z (ESI): 508.05 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.24(s,1H),7.75 (s,2H),7.52-7.47 (m,1H),7.45-7.40 (m,1H),7.38-7.31 (m,1H),7.19-7.02 (m,3H),6.61-6.47 (m,1H),2.02-1.91(m,1H),1.01-0.93(m,2H),0.75-0.67(m,2H).

[0190] Example 32 2-(3,5-dichloro-4-((6-oxo-1-(thiophen-3-yl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0191] [ka]

[0192] Using the method of Example 20, substituting 3-thiopheneboronic acid for phenylboronic acid, the title product, 2-(3,5-dichloro-4-((6-oxo-1-(thiophen-3-yl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile KPC00134 (50.0 mg, white solid, 97.83% yield). MS m / z (ESI): 473.98 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 13.23(s,1H),7.85-7.70 (m,3H),7.65-7.57 (m,1H),7.54-7.43 (m,2H),7.27 (d,J = 4.0 Hz,2H),6.54 (d,J = 12.0 Hz 1H).

[0193] Example 33 2-(3,5-dichloro-4-((6-oxo-1-(thiophen-2-yl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0194] [ka]

[0195] Using the method of Example 1, substituting 2-bromothiophene for isopropyl iodide, the title product, 2-(3,5-dichloro-4-((6-oxo-1-(thiophen-2-yl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 33 (130.0 mg, white solid, 19.71% yield). MS m / z (ESI): 473.90 [M+1] + .

[0196] Example 34 2-(3,5-dichloro-4-((6-oxo-1-(thiazol-2-yl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0197] [ka]

[0198] Using the method of Example 1, substituting 2-bromothiazole for isopropyl iodide, the title product 2-(3,5-dichloro-4-((6-oxo-1-(thiazol-2-yl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 34 (13.0 mg, white solid, 22.48% yield) was prepared. MS m / z (ESI): 474.90 [M+1] + . 1 H NMR (400 MHz,DMSO-d6),8.13 (d,J = 3.2 Hz,1 H),7.88 (s,2 H),7.84 (dd,J = 10.0,4.0 Hz,1 H),7.74 (d,J = 4.0 Hz,1 H),7.62 (d,J = 4.0 Hz,1 H),6.91 (d,J = 10.0 Hz,1 H).

[0199] Examples 35 / 36 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-methyl-1,2,4-triazine-3,5(2H,4H)-dione

[0200] [ka]

[0201] First step 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate methyl ester 2-(3,5-Dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 20 (1.50 g, 1.60 mmol) was dissolved in 15 mL of anhydrous methanol, and then thionyl chloride (2.50 mL, 34.46 mmol) was added dropwise at room temperature. The mixture was then reacted at 100°C for 4 hours. The mixture was cooled to room temperature, the solvent was concentrated, water was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The mixture was dried over anhydrous sodium sulfate, filtered, mixed with silica gel, and purified by column chromatography (PE:EA = 0-100%) to give methyl 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate 35a (1.45 g, red solid) in a yield of 66.62%. MS m / z (ESI): 501.00 [M+1] + . Second step 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(hydroxymethyl)-1,2,4-triazine-3,5(2H,4H)-dione Methyl 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate 35a (1.45 g, 1.93 mmol) was dissolved in 15 mL of anhydrous tetrahydrofuran, and then triethylamine (0.20 g, 1.93 mmol) was added at 20°C and stirred for 10 minutes. Sodium borohydride (0.07 g, 1.93 mmol) was then added, followed by the slow dropwise addition of 5.0 mL of anhydrous methanol, and the mixture was allowed to react at 20°C for 20 minutes. The reaction was quenched with water, and the solvent was evaporated on a rotary evaporator. Water was added to the reaction mixture, which was then extracted three times with ethyl acetate, dried over anhydrous sodium sulfate, filtered, mixed with silica gel, and purified by column chromatography (PE:EA = 0-100%) to give 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(hydroxymethyl)-1,2,4-triazine-3,5(2H,4H)-dione 35b (0.83 g, red solid) in a 74.83% yield. MS m / z (ESI): 472.95 [M+1] + Third step 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-methyl-1,2,4-triazine-3,5(2H,4H)-dione 2-(3,5-Dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(hydroxymethyl)-1,2,4-triazine-3,5(2H,4H)-dione 35b (680 mg, 1.18 mmol) was added to 10 mL of dichloromethane, and then DAST (380.4 mg, 2.36 mmol) was added dropwise slowly, followed by reaction at 20°C for 10 minutes. The reaction was quenched by adding water, then extracted three times, dried over anhydrous sodium sulfate, filtered, evaporated on a rotary evaporator, and purified by Prep-HPLC (column model: Welch Ultimate XB-C18, 21.2*250 mm, 10 μm, mobile phase: A: 0.05% TFA aqueous solution, B: acetonitrile) to obtain 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione (142.4 mg, white solid) 35 (142.4 mg, white solid, yield: 25.19%). MS m / z (ESI): 474.95 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 12.66 (s,1H),7.81 (s,2H),7.55 - 7.46 (m,3H),7.45 - 7.40 (m,1H),7.39 - 7.33 (m,3H),6.54 (d,J = 10.0 Hz,1H),5.28 (d,J = 46.8 Hz,2H). Simultaneously, 2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-methyl-1,2,4-triazine-3,5(2H,4H)-dione 36 (26.8 mg, white solid) was obtained. MS m / z (ESI): 457.27 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 7.80 (s,2H),7.62 - 7.23 (m,7H),6.54 (d,J = 10.0 Hz,1H),2.15 (s,3H).

[0202] Example 37 2-(3,5-dichloro-4-((1-(4-fluorophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione

[0203] [ka]

[0204] Using the method of Example 35 and starting from 21, the title product, 2-(3,5-dichloro-4-((1-(4-fluorophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione 37 (164.0 mg, white solid, 34.82% yield) was prepared. MS m / z (ESI): 493.25 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 12.67 (s,1H),7.80 (s,2H),7.51 (dd,J = 10.0,4.0 Hz,1H),7.46 - 7.38 (m,3H),7.36 - 7.26 (m,2H),6.54 (d,J = 10.0 Hz,1H),5.28 (d,J = 46.8 Hz,2H).

[0205] Example 38 2-(3,5-dichloro-4-((1-(3-fluorophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione

[0206] [ka]

[0207] Using the method of Example 35 and starting from 22, the title product, 2-(3,5-dichloro-4-((1-(3-fluorophenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione 38 (20.0 mg, white solid, 26.6% yield) was prepared. MS m / z (ESI): 493.05 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 12.67 (s,1H),7.80 (s,2H),7.68-7.45 (m,3H),7.36-7.28 (m,2H),7.25-7.19 (m,1H),6.55 (d,J = 8.0 Hz,1H),5.26 (d,J = 48.0 Hz,2H).

[0208] Example 39 2-(3,5-dichloro-4-((6-oxo-1-(3-(trifluoromethyl)phenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione

[0209] [ka]

[0210] Using the method of Example 35 and starting from 23, the title product, 2-(3,5-dichloro-4-((6-oxo-1-(3-(trifluoromethyl)phenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione 39 (4.0 mg, white solid, 96.6% yield) was prepared. MS m / z (ESI): 543.02 [M+1] + . 1H NMR (400 MHz,DMSO-d6) δ 12.72(s,1H),7.89-7.79 (m,4H),7.77-7.71 (m,1H),7.70-7.66 (m,1H),7.59 (d,J = 4.0 Hz,1H),7.52(dd,J = 4.0,4.0 Hz,1H),6.56 (d,J = 12.0 Hz,1H),5.28 (d,J = 48.0 Hz,2H).

[0211] Example 40 2-(3,5-dichloro-4-((6-oxo-1-(3-(trifluoromethoxy)phenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione

[0212] [ka]

[0213] Using the method of Example 35 and starting from 24, the title product, 2-(3,5-dichloro-4-((6-oxo-1-(3-(trifluoromethoxy)phenyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione 40 (8.0 mg, white solid, 50.6% yield) was prepared. MS m / z (ESI): 559.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 7.81 (s,2H),7.52-7.47 (m,1H),7.45-7.36 (m,5H),6.55 (d,J = 8.8 Hz,1H),5.27 (d,J = 48.0 Hz,2H).

[0214] Example 41 2-(3,5-dichloro-4-((6-oxo-1-(p-tolyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione

[0215] [ka]

[0216] Using the method of Example 35 and starting from 25, the title product, 2-(3,5-dichloro-4-((6-oxo-1-(p-tolyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione 41 (8.5 mg, pale yellow solid, 3.0% yield) was prepared. MS m / z (ESI): 489.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 7.81 (s,2H),7.51-7.45 (m,1H),7.41-7.17 (m,5H),6.53 (d,J = 8.0 Hz,1H),5.27 (d,J = 48.0 Hz,2H),2.34 (s,3H).

[0217] Example 42 2-(3,5-dichloro-4-((1-(3,5-dimethylphenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione

[0218] [ka]

[0219] Using the method of Example 35 and starting from 30, the title product, 2-(3,5-dichloro-4-((1-(3,5-dimethylphenyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione 42 (280.00 mg, white solid, 44.9% yield) was prepared. MS m / z (ESI): 503.31 [M+1] + . 1H NMR (400 MHz,DMSO-d6) δ 12.68 (s,1H),7.81 (s,2H),7.47 (dd,J = 10.0,3.6 Hz,1H),7.32 (d,J = 3.6 Hz,1H),7.06 (s,1H),6.95 (s,2H),6.52 (d,J = 10.0 Hz,1H),5.29 (d,J = 46.8 Hz,2H),2.30 (s,6H).

[0220] Example 43 2-(3,5-dichloro-4-((6-oxo-1-(thiophen-2-yl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione

[0221] [ka]

[0222] Using the method of Example 35 and starting from 33, the title product, 2-(3,5-dichloro-4-((6-oxo-1-(thiophen-2-yl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione 43 (1.98 mg, white solid, 3.9% yield) was prepared. MS m / z (ESI): 480.95 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 12.69 (s,1H),7.93 (d,J = 4.0 Hz,1H),7.83 (s,2H),7.49-7.35 (m,3H),7.03 (s,1H),6.64 (d,J = 12.0 Hz,1H),5.29 (d,J = 36.0 Hz,2H).

[0223] Example 44 2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione

[0224] [ka]

[0225] Using the method of Example 35 and starting from 1, the title product, 2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione 44 (150.0 mg, white solid, 35.0% yield) was prepared. MS m / z (ESI): 441.00 [M+1] + . 1 H NMR (400 MHz,DMSO-d6) δ 12.68 (s,1H),8.10 (s,2H),7.51 (d,J = 4.0 Hz,1H),7.24-7.17 (m,1H),6.41-6.32 (m,1H),5.99 (d,J = 40.0 Hz,2H),5.04-4.98 (m,1H),1.25 (d,J = 4.0 Hz,6H).

[0226] Example 45 2-(3,5-dichloro-4-((1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione

[0227] [ka]

[0228] Using the method of Example 35 and starting from 8, the title product, 2-(3,5-dichloro-4-((1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-6-(fluoromethyl)-1,2,4-triazine-3,5(2H,4H)-dione 45 (114.0 mg, white solid, 46.0% yield) was prepared. MS m / z (ESI): 467.00 [M+1]+ . 1 H NMR (400 MHz,DMSO-d6) δ 12.68 (s,1H),7.82 (s,2H),7.42-7.40 (m,1H),7.30 (s,1H),6.43 (d,J = 8.0 Hz,1H),5.29 (d,J = 44.0 Hz,2H),4.00 (t,J = 8.0 Hz,2H),3.49 (t,J = 8.0 Hz,2H),3.19(s,3H).

[0229] Example 46 2-(3,5-dichloro-4-((3-methyl-5-oxo-1,2,3,5-tetrahydroindolin-8-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

[0230] [ka]

[0231] First step 3-Bromo-2-(3-buten-1-yl)-6-methoxypyridine 3-Bromo-6-methoxy-2-methylpyridine 46a (5.0 g, 24.75 mmol) was dissolved in anhydrous tetrahydrofuran (100 mL). Under nitrogen gas protection, lithium diisopropylamide (27.23 mL, 54.45 mmol) was added dropwise at -78 °C. The mixture was then incubated at -50 °C for 40 minutes. 3-Bromopropene (6.587 g, 54.45 mmol) was then added. The mixture was then incubated at -50 °C for 30 minutes, then allowed to warm to room temperature and incubated for 16 hours. The reaction was quenched with 3 mL of saturated aqueous ammonium chloride solution, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give 3-bromo-2-(3-buten-1-yl)-6-methoxypyridine 46b (3.79 g, colorless oil) in 53.43% yield. MS m / z (ESI): 242.01 [M+1] + . Second step 5-Bromo-6-(3-iodobutyl)pyridin-2(1H)-one 3-Bromo-2-(3-buten-1-yl)-6-methoxypyridine 46b (2.38 g, 9.83 mmol) was dissolved in hydroiodic acid (20.0 mL) and reacted at 65 °C for 2 h. 100 mL of water was added, extracted with ethyl acetate (100 mL * 3), washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give 5-bromo-6-(3-iodobutyl)pyridin-2(1H)-one 46c (3.33 g, black oil) in 95.14% yield. MS m / z (ESI): 355.91 [M+1] + . Third step 8-Bromo-3-methyl-2,3-dihydroindolin-5(1H)-one 5-Bromo-6-(3-iodobutyl)pyridin-2(1H)-one 46c (3.33 g, 9.35 mmol) was dissolved in 60.0 mL of ethanol, potassium hydroxide (1.57 g, 28.05 mmol) was added, and the mixture was reacted at 25 °C for 30 min. The mixture was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography to give 8-bromo-3-methyl-2,3-dihydroindolin-5(1H)-one 46d (1.40 g, white solid) in 65.65% yield. MS m / z (ESI): 227.99 [M+1] + . Fourth step 3-Methyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxapentan-2-yl)-2,3-dihydroindolin-5(1H)-one Dihydroindolin-5(1H)-one 46d (1.18 g, 5.17 mmol) was dissolved in 1,4-dioxane (24.0 mL), and boric acid pinacol ester (2.63 g, 10.34 mmol), potassium acetate (1.01 g, 10.34 mmol), and 1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (378.0 mg, 0.52 mmol) were added. The mixture was purged with nitrogen gas three times and refluxed for 16 hours. The mixture was concentrated under reduced pressure to remove the solvent, and the resulting mixture was purified by column chromatography to give 3-methyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxapentan-2-yl)-2,3-dihydroindolin-5(1H)-one 46e (550.0 mg, white solid) in 38.6% yield. MS m / z (ESI): 276.17 [M+1] + . Fifth step 8-Hydroxy-3-methyl-2,3-dihydroindolin-5(1H)-one 3-Methyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxapentan-2-yl)-2,3-dihydroindolin-5(1H)-one 46e (550.0 mg, 2.0 mmol) was dissolved in a mixed solvent of 12.0 mL of tetrahydrofuran and 2.0 mL of water, and 30% hydrogen peroxide (680.0 mg, 6.0 mmol) was added. The mixture was incubated at 25 °C for 16 hours, and then ethyl acetate (30 mL) was added. The mixture was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give 8-hydroxy-3-methyl-2,3-dihydroindolin-5(1H)-one 46f (280.0 mg, white solid) in 84.75% yield. MS m / z (ESI): 166.08 [M+1] + . Sixth step 8-(2,6-Dichloro-4-nitrophenoxy)-3-methyl-2,3-dihydroindolin-5(1H)-one 8-Hydroxy-3-methyl-2,3-dihydroindolin-5(1H)-one 46f (92.5 mg, 0.56 mmol) was dissolved in 2.0 mL of N,N-dimethylformamide, and 1,3-dichloro-2-fluoro-5-nitrobenzene (117.6 mg, 0.56 mmol) and potassium carbonate (232.2 mg, 1.68 mmol) were added. The mixture was allowed to react at 25 °C for 2 hours, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to give 8-(2,6-dichloro-4-nitrophenoxy)-3-methyl-2,3-dihydroindolin-5(1H)-one 46g (100.0 mg, white solid) in 50.28% yield. MS m / z (ESI): 355.02 [M+1] + . Seventh step 8-(4-amino-2,6-dichlorophenoxy)-3-methyl-2,3-dihydroindolin-5(1H)-one 8-(2,6-Dichloro-4-nitrophenoxy)-3-methyl-2,3-dihydroindolin-5(1H)-one 46g (480 mg, 1.35 mmol) was dissolved in a mixed solvent of 10 mL of ethanol and 10 mL of saturated ammonium chloride, and reduced iron powder (377 mg, 6.75 mmol) was added. The mixture was refluxed for 2 hours, filtered, concentrated to remove the ethanol, extracted with dichloromethane (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give 8-(4-amino-2,6-dichlorophenoxy)-3-methyl-2,3-dihydroindolin-5(1H)-one 46h (220.0 mg, colorless oil) in 50.0% yield. MS m / z (ESI): 325.04 [M+1] + . Eighth step Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((3-methyl-5-oxo-1,2,3,5-tetrahydroindolin-8-yl)oxy)phenyl)hydrazone)acetyl)carbamate 8-(4-amino-2,6-dichlorophenoxy)-3-methyl-2,3-dihydroindolin-5(1H)-one 46h The resulting mixture (150.0 mg, 0.46 mmol) was dissolved in a mixed solvent consisting of 3.2 mL of acetic acid, 0.8 mL of water, and 0.4 mL of concentrated hydrochloric acid. Sodium nitrite (33.3 mg, 0.48 mmol) was added at 0°C, and the mixture was allowed to react for 10 minutes. After that, sodium acetate (113.2.0 mg, 1.38 mmol) was added, and the mixture was allowed to react for another 10 minutes. N-cyanoacetylurethane (143.6 mg, 0.92 mmol) was added, and the mixture was warmed to room temperature and allowed to react for 72 hours. 5 mL of water was added, and the mixture was filtered and dried by heating to obtain ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((3-methyl-5-oxo-1,2,3,5-tetrahydroindolin-8-yl)oxy)phenyl)hydrazone)acetyl)carbamate 46i (180.0 mg, yellow solid) in a yield of 79.5%. MS m / z (ESI): 492.08 [M+1] + . 9th step 2-(3,5-dichloro-4-((3-methyl-5-oxo-1,2,3,5-tetrahydroindolin-8-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile Ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((3-methyl-5-oxo-1,2,3,5-tetrahydroindolin-8-yl)oxy)phenyl)hydrazone)acetyl)carbamate 46i (180.0 mg, 0.37 mmol) was dissolved in 3.0 mL of N,N-dimethylacetamide, and potassium acetate (108.9 mg, 1.11 mmol) was added. The mixture was reacted at 120 °C for 2 hours, concentrated under reduced pressure to remove the solvent, and purified by preparative chromatography to give 2-(3,5-dichloro-4-((3-methyl-5-oxo-1,2,3,5-tetrahydroindolin-8-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 46 (60.0 mg, white solid) in a 35.3% yield. MS m / z (ESI): 446.03 [M+1] + . 1H NMR (400 MHz,DMSO-d6) δ 13.26(s,1H),7.77 (s,2H),7.02 (d,J = 12.0 Hz,1H),6.13 (d,J = 8.0 Hz,1H),4.72-4.68 (m,1H),3.26-3.11(m,2H),2.37-2.32 (m,1H),1.91-1.88(m,1H),1.32(d,J = 8.0 Hz,2H).

[0232] Example 47 THRβ binding experiment Experimental Methods: In vitro analysis of compound agonism for THRβ was performed using a time-resolved fluorescence resonance energy transfer (FER) assay for coactivator peptide recruitment. The experiments used biotin-SRC2-2 coactivator peptide, streptavidin-d2, RXRα, and GST-tagged THRβ-LBD Eu-anti-GST antibody. The Eu-anti-GST antibody indirectly labeled THRβ-LBD by binding to the GST tag. Streptavidin-d2 indirectly labeled SRC2-2 coactivator peptide by binding to the biotin tag. In the presence of RXRα, THRβ-LBD can form a heterodimer with it: THRβ-LBD / RXRα. Agonists bind to THRβ-LBD / RXRα and induce a conformational change in THRβ-LBD, thereby increasing its ability to recruit the heterodimer to the SRC2-2 coactivator peptide. This simultaneously decreased the distance between the d2-labeled SRC2-2 coactivator peptide and the Eu-anti-GST antibody, resulting in an increased THR-FRET signal. The agonistic ability of compounds can be assessed by examining the effects of different concentrations of compounds on THRβ activity. The detailed steps are as follows: a. 100X reference compound or compound was prepared in DMSO and diluted 1:3 to the same factor. b. A 100X gradient dilution of reference compound or compound was diluted 4X with 1X reaction buffer and added to a multi-well plate. c. A mixed solution of 4X THRβ-LBD and 4X RXRα was prepared using 1X reaction buffer and added to a multi-well plate. d. A mixed solution of 2X biotin-SRC2-2, 2X Eu-anti-GST, and 2X streptavidin-d2 was prepared using 1X reaction buffer and added to the multiwell plate. e. The mixture was centrifuged at 1000 rpm for 1 minute and incubated at room temperature in the dark for 4 hours. f. The fluorescence signal values ​​at 665 nm and 615 nm were read using an EnVision 2104 board reader, and the ratio 665nm / 615nm was calculated. The experimental results are shown in Table 1.

[0233] [Table 1]

[0234] Example 48 THRα binding experiment Experimental Methods: In vitro analysis of compound agonism on THRα used methods similar to those used for the THRβ binding experiments in Example 49, except that THRα was used instead of THRβ. The experimental results are shown in Table 2.

[0235] [Table 2]

[0236] Conclusion: Compared to the disclosed control compound 2, several compounds according to the present invention exhibit unexpectedly high THRβ activity, and several compounds exhibit higher selectivity for THRβ than control compound 2.

[0237] Example 49 In vitro liver microsome stability assay Experimental Method: (1) Solution preparation The test substance and verapamil as a positive control were each dissolved in DMSO to 10 mM to prepare a stock solution, and the 10 mM stock solution was diluted with 70% aqueous acetonitrile to a concentration of 0.25 mM. An NADPH regenerating system was prepared containing final concentrations of 6.5 mM NADP, 16.5 mM G-6-P, 3 U / mL G-6-PDH, and 3.3 mM magnesium chloride. The stop solution was an acetonitrile solution containing tolbutamide and propranolol (both internal standards). The phosphate buffer is a 100 mM K3PO4 (pH=7.4) buffer containing 3.3 mM MgCl2. The liver microsome incubation system contains 0.2 mg / mL liver microsomal protein and 1 μM test article / positive control in 100 mM phosphate buffer. (2) Incubation process 80 μL of the mixture was taken from the incubation system, and 400 μL of stop solution was added to precipitate the proteins. After vortexing, 20 μL of NADPH regeneration system was added to set the 0 min sample point. To the remaining 520 μL of the protein-drug mixture, 130 μL of NADPH regenerating system was added and mixed thoroughly. The final incubation system was 650 μL and contained 0.2 mg / mL liver microsomal protein, 1 μM test substance / positive control, 1.3 mM NADP, 3.3 mM G-6-P, and 0.6 U / mL G-6-PDH. The mixture was incubated in a 37°C water bath with gentle shaking. 100 μL of the incubation solution was collected at 5, 10, 30, and 60 minutes, and placed in a new 96-well plate containing 400 μL of stop solution per well. The mixture was mixed uniformly and the proteins were precipitated (centrifuged at 4000 × g for 15 minutes at 4°C). 100 μL of the supernatant was collected and diluted with water in a ratio of 1:2, after which the sample was analyzed by LC-MS / MS method. The experimental results are shown in Table 3.

[0238] [Table 3]

[0239] The above test results indicate that most of the aromatic-substituted pyridone compounds have excellent stability in liver microsomes.

[0240] Example 50: In vivo pharmacokinetic evaluation in mice Mice were used as test animals, and the compounds of Example 1 and Example 46 were intragastrically administered to mice, followed by measurement of blood drug concentrations at different time points. The in vivo pharmacokinetic behavior of the compounds of the present invention in mice was studied, and their drug metabolism characteristics were evaluated. In this example, healthy adult male ICR mice with similar body weights were selected and administered a single oral dose of 3.0 mg / kg. Whole blood samples were collected before administration and at 1, 2, 4, 6, 8, 12, 24, and 48 hours after administration. An LC / MS / MS method was established to measure the concentration of unchanged drug in plasma samples. Key pharmacokinetic parameters were calculated using the WinNonlin 6.3 NCA model. Experimental Method: Experimental drugs: the compounds of Example 1 and Example 46 obtained in the above examples. Experimental animals: Nine healthy adult male ICR mice were divided into three groups, with three mice per group. Shanghai Xipuer-Bikai Laboratory Animal Co., Ltd., Animal Certificate Number: SCXK(Hu)2018-0006 2018 0006 010467. Pharmaceutical preparation: A fixed amount of each compound of Example 1 and Example 46 was accurately weighed and placed in a 15 mL sample tube. 5 μL of Tween 80 was added to wet the tube. 5.2 mL of 2% hydroxypropylmethylcellulose (HPMC) solution was then added, and the mixture was vortexed thoroughly while sonicating to obtain a homogeneous suspension. The suspension was freshly prepared immediately before use. Administration: After overnight fasting, ICR mice were intragastrically administered with 3.0 mg / kg of acetaminophen. Ta. Procedure: Mice were intragastrically administered with the compounds of Example 1 and Example 46, respectively. Whole blood samples were collected before administration and 1, 2, 4, 6, 8, 12, 24, and 48 hours after administration. The samples were anticoagulated with sodium heparin, centrifuged at 4°C for 5 minutes to separate the plasma, and then stored at -80°C. Measurement of the content of test compound in the plasma of mice administered intragastrically: After administration of the compounds of Example 1 and Example 46, 12.5 μL of plasma from each test mouse was collected at each time point, mixed in pairs, and added with 100 μL of internal standard solution and 125 μL of methanol. The mixture was vortexed for 2 minutes and centrifuged at 4°C and 13,000 rpm for 10 minutes. The supernatant was collected and used for LC-MS / MS analysis. The results of the pharmacokinetic parameters are shown in Table 4.

[0241] [Table 4]

[0242] Conclusion: The compounds of the present invention have good pharmacological activity, and in particular, the cyclic structure has more advantageous pharmacological activity, good pharmacokinetic absorption, and obvious pharmacokinetic advantages. It was found that, at comparable doses and formulations, some compounds of the present invention exhibit unexpectedly high Cmax values ​​and exposures, as well as long half-lives. All of the above PK results indicate that the compounds provided by the present invention have favorable PK properties and can be used as therapeutic agents for metabolic diseases. It should be understood in the art that the above compounds can exert their pharmacological and pharmacokinetic advantages in the preparation of pharmaceutical compositions. The above description of the examples is only used to help understand the method and core concept of the present invention. It should be noted that a person skilled in the art can make some improvements and modifications to the present invention without departing from the principle of the present invention, and these improvements and modifications also fall within the protection scope of the present invention.

Claims

1. A 2-pyridone derivative having a structure represented by formula I or a pharma- ceutically acceptable salt thereof. 【Chemistry 1】 (In the formula, R 1 is C 5~10 Aryl group or C 5~10 heteroaryl group, 5~10 Aryl group or C 5~10 The heteroaryl group may be one or more halogen, substituted or unsubstituted C 1~6 Alkyl group, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 alkoxy or cyano groups, said C 1-6 alkyl, C 3-6 cycloalkyl or C 1-6 alkoxy groups being optionally substituted by one or more fluorine atoms; R 2 is hydrogen or C 1~6 selected from alkyl groups, R 3 is hydrogen, halogen, C 1~6 Alkyl group or C 3~6 cycloalkyl groups, R 4 are independently hydrogen, a hydroxyl group, C 1~6 Alkyl group, halogen, C 1~6 Alkoxy group, or C 3~6 cycloalkyl groups or two adjacent R 4 is C 3~6 Forms a cycloalkyl group, wherein the C 1~6 Alkyl group, C 3~6 Cycloalkyl group or C 1~6 The alkoxy group may be further optionally substituted with one or more hydroxyl groups or halogens; n is 1, 2 or 3; R 5 is hydrogen, a cyano group, a carboxyl group, C 1~6 Alkyl group, or C 3~6 cycloalkyl group, 1~6 Alkyl group, C 3~6 The cycloalkyl group may be substituted with one or more halogens, hydroxyl groups, or C l~6 may be optionally substituted with an alkoxy group; R 6 is hydrogen or C 1~6 selected from alkyl groups, L is -CH 2 -, -O-, -CF 2 -S- or -S-; X is selected from O or S; Or, R 1 and R 2 together with the atom to which they are attached form a 4- to 10-membered heterocycloalkyl group, said heterocycloalkyl group being R 1 In addition to the nitrogen atom originally attached to, the heterocycloalkyl group may further contain zero, one or two optional oxygen, sulfur and nitrogen atoms, and the heterocycloalkyl group may further contain one or more l -C 6 It may be optionally substituted with an alkyl group, a hydroxyl group, a halogen, or a cycloalkyl group.

2. The above R 1 is selected from a phenyl group, a thienyl group, or a thiazolyl group; The phenyl, thienyl, or thiazolyl group may be one or more halogen, substituted or unsubstituted C 1~6 Alkyl group, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 The 2-pyridone derivative or a pharma- ceutically acceptable salt thereof according to claim 1, wherein the C1-6 alkyl group, the C3-6 cycloalkyl group, or the C1-6 alkoxy group is optionally substituted with one or more fluorine atoms.

3. 2. The 2-pyridone derivative or a pharma- ceutically acceptable salt thereof according to claim 1, having any one of the structures of formulae IIa to IIc. 【Chemistry 2】 (In the formula, R 1b is C 5~10 Aryl group or C 5~10 heteroaryl group, 5~10 Aryl group or C 5~10 The heteroaryl group may further include halogen, substituted or unsubstituted C 1~6 Alkyl group, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 alkoxy groups, or cyano groups, wherein the C 1-6 alkyl groups, C 3-6 cycloalkyl groups, or C 1-6 alkoxy groups are optionally substituted by one or more fluorine atoms; In formula IIc, the A ring is a 4-10 membered heterocycloalkyl group containing a nitrogen-bonded atom, where said 4-10 membered heterocycloalkyl group may further contain zero, one or two optional oxygen, sulfur and nitrogen atoms in addition to the original nitrogen-bonded atom, and said heterocycloalkyl group may further contain one or more C l -C 6 Optionally substituted with alkyl groups, hydroxyl groups, halogens, cycloalkyl groups, R 5 is hydrogen, a cyano group, a carboxyl group, C 1~6 Alkyl group, C 3~6 cycloalkyl group, 1~6 Alkyl group, C 3~6 The cycloalkyl group may be one or more of a halogen, a hydroxyl group, a C l~6 It may be optionally substituted with an alkoxy group.

4. The 2-pyridone derivative or a pharma- ceutically acceptable salt thereof according to claim 3, wherein, in the formula IIc, ring A is a 5- to 6-membered monocyclic heterocyclic group or a 7- to 10-membered spiro heterocyclic group.

5. In the above formula IIc, ring A is a 5- or 6-membered monocyclic heterocyclic group; The 5- or 6-membered monocyclic heterocyclic group may be one or more of halogen, C 1~3 Alkyl group, or C 3~6 5. The 2-pyridone derivative or a pharma- ceutically acceptable salt thereof according to claim 4, which may be optionally substituted with a cycloalkyl group.

6. R 1b is selected from a phenyl group, a thienyl group, or a thiazolyl group; The phenyl, thienyl, or thiazolyl group may be one or more halogen, substituted or unsubstituted C 1~6 Alkyl group, substituted or unsubstituted C 3~6 Cycloalkyl groups, substituted or unsubstituted C 1~6 The 2-pyridone derivative or a pharma- ceutically acceptable salt thereof according to claim 3, wherein the C 1-6 alkyl group, the C 3-6 cycloalkyl group or the C 1-6 alkoxy group is optionally substituted by one or more fluorine atoms.

7. The above R 5 is hydrogen, a cyano group or C 1~6 selected from alkyl groups, The above C 1~6 4. The 2-pyridone derivative or the pharma- ceutically acceptable salt thereof according to claim 1 or 3, wherein the alkyl group is optionally substituted with one or more halogen or hydroxyl groups.

8. The above R 5 is a hydrogen atom, a cyano group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a neopentyl group, or -CH(CH 2 CH 3 ) 2 Selected from The above-mentioned methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group or -CH(CH 2 CH 3 ) 2 The 2-pyridone derivative or a pharma- ceutically acceptable salt thereof according to claim 7, wherein: is optionally substituted with one to three fluorine atoms.

9. The above R2 is H, The above R3 is H, R4 is ortho-difluoro, ortho-dichloro, or ortho-dibromo at the L position; The above R6 is H, The L is -O-, 2. The 2-pyridone derivative or a pharma- ceutically acceptable salt thereof according to claim 1, wherein X is O.

10. 2. The 2-pyridone derivative or a pharma- ceutically acceptable salt thereof according to claim 1, having any one of the following structures: 【Chemistry 3】 【Chemistry 4】 【Chemistry 5】 【Chemistry 6】 【Chemistry 7】 【Chemistry 8】 【Chemistry 9】 【Chemistry 10】 【Chemistry 11】

11. A pharmaceutical composition for use in the prevention, treatment and / or alleviation of diseases caused by thyroid hormone receptor dysregulation, comprising the 2-pyridone derivative or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 10.

12. The pharmaceutical composition of claim 11, characterized in that the disease caused by thyroid hormone receptor dysregulation includes one or more of obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, atherosclerosis, cardiovascular disease, hypothyroidism, and thyroid cancer.

13. A pharmaceutical formulation comprising the 2-pyridone derivative or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 10, and a pharma- ceutically acceptable excipient.

Citation Information

Patent Citations

  • Pyridazinone derivatives as thyroid hormone receptor agonists

    JP2009501759A

  • Compounds as thyroid hormone beta receptor agonists and their uses

    JP2022549009A

  • Combination therapy for the treatment of liver disease

    WO2020049556A1

  • Novel compounds and their uses as thyroid hormone receptor agonists

    WO2020169069A1

  • Modulators of THR-β and methods of use thereof

    WO2020227549A1